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ABSTRACT 
Background: Knee osteoarthritis (OA) is the most common type of OA and is a major 
cause of pain and thus results in disability for daily activities among persons living in the 
community. OA currently has no cure. In addition to the conflicting recommendations 
from clinical guidelines, evidence about the extent to which long-term use of intra-
articular injections improves patient outcomes is also lacking.  
Methods: Using data from the Osteoarthritis Initiative (OAI), marginal structural models 
(MSMs) applying inverse probability treatment weights (IPTW) were used to examine 
the effectiveness of intra-articular injections and changes in symptoms over time. The 
specific aims of this dissertation were to: 1) evaluate longitudinal use of intra-articular 
injections after treatment initiation among persons with radiographic knee OA; 2) 
quantify the extent to which intra-articular injection relieves symptoms among persons 
with radiographic knee OA; and 3) evaluate the performance of missing data techniques 
under the setting of MSMs. 
Results: Of those initiating injections, ~19% switched, ~21% continued injection type, 
and ~60% did not report any additional injections.  For participants initiating 
corticosteroid (CO) injections, greater symptoms post-initial injection rather than changes 
in symptoms over time were associated with continued use compared to one-time use. 
Among participants with radiographic evidence of knee OA, initiating treatments with 
either CO or hyaluronic acid (HA) injections was not associated with reduced symptoms 
compared to non-users over two years. Compared to inverse probability weighting (IPW), 
missing data techniques such as multiple imputation (MI) produced less biased marginal 
 
 
vii 
 
causal effects  (IPW: -2.33% to 15.74%; -1.88% to 4.24%). For most scenarios, estimates 
using MI had smaller mean square error (range: 0.013 to 0.024) than IPW (range: 0.027 
to 0.22). 
Conclusions: Among participants with radiographic evidence of knee OA living in the 
community, the proportion of those switching injection use and one-time users was 
substantial after treatment initiation. In addition, initiating injection use was not 
associated with reduced symptoms over time. With respect to issues of missing data, 
using MI may confer an advantage over IPW in MSMs applications. The results of this 
work highlight the importance of using comparative effectiveness research with non-
experimental data to study these commonly used injections and may help to understand 
the usefulness of these treatments for patients with knee OA. 
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CHAPTER I 
 INTRODUCTION 
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Knee Osteoarthritis among the U.S. population 
Osteoarthritis (OA) is a chronically degenerative condition involving changes in 
muscular and cartilage tissues around the joint. OA may develop in any joints, but the 
most commonly affected joints are the knee, hip, hand, spine, and foot. In 2005, nearly 27 
million of U.S. adults were affected by OA.1 Knee OA is the most common type of OA 
with nearly 6.1% of U.S. adults who are aged 30 or older having this disease.2–4 The 
prevalence and incidence of knee OA increases with age. Among participants in the 
Framingham Study, the prevalence of knee OA was 19.2% in those aged over 45 years 
and 43.7% in those over 80 years.5 In adults aged over 20 years, the incidence rate of 
knee OA has been estimated to be 240/100,000 person-years and approximately 2% per 
year developed incident radiographic disease among women.6,7  
The risk factors of developing OA, including both systematic and local elements, 
have been identified. Systemic factors are those that may act by increasing the 
susceptibility of joints to injury or by impairing the process of repair such as age, gender 
and hormones, race/ethnicity, and genetics.8,9 Local factors are those biomechanical 
elements that adversely affect the forces applied to the joints such as obesity, history of 
injury or surgery, occupation, physical activity and sports.8,9 Clinical symptoms of OA 
include joint pain, stiffness, and limitations of movements. Symptomatic knee OA is 
defined by the presence of pain, aching, or stiffness in a joint with clinical radiographic 
evidence. Approximately 10% of women and 13.6% of men over 60 years of age have 
symptomatic knee OA.10 Although disease progression of OA is usually slow, it can 
ultimately lead to joint failure with pain and disability. Disease in weight bearing joints 
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such as the knee has a greater clinical impact. Knee OA is 1 of the 5 leading causes of 
disability among non-institutionalized adults.11 
 
Use of Intra-articular Injections and Outcomes in Knee Osteoarthritis 
 Although knee OA is a major cause of pain and disability among persons living in 
the community, OA currently has no cure, as the mechanism by which it arises and 
progresses remains incompletely understood. Goals of OA treatment using non-
pharmacologic or pharmacologic modalities include pain relief, improved mobility, 
delayed disease progression, and improved quality of life. Patients with a clinical 
diagnosis of knee OA are often treated primarily with conservative treatment plans 
including a combination of non-pharmacologic and pharmacologic agents. If non-
pharmacologic intervention such as exercise or weight management and/or the use of 
orally administered medications such as acetaminophen are ineffective, intra-articular 
injections may offer symptom relief. 12–14  
Currently, there are two primary types of intra-articular injections used in OA:  
corticosteroid (CO) injections and viscosupplementation (hyaluronic acid (HA) 
injections). For CO injections, there are 5 formulations that have been approved by the 
US Food and Drug Administration.14 CO injections reduce inflammation which indirectly 
may relieve pain for up to 4 weeks. Typically, no more than three corticosteroid 
injections a year are recommended. Although there are several formulations available for 
corticosteroid injections, they are thought to be equally efficacious15–18 with most clinical 
guidelines advising consideration of such injections for acute exacerbations or short-term 
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relief.19–21 On the other hand, HA is a naturally occurring constituent of cartilage and 
synovial fluid in the joints. HA injections have a different mechanism of action including 
enhancing and maintaining inter-articular lubrication while potentially providing 
additional protection such as anti-inflammatory action, analgesic and chondroprotective 
effects.22 Treatment cycles for these injections can consist of up to five weekly injections 
and may offer relief for up to six months thus providing longer term benefits compared to 
corticosteroids.23   
Patient-focused evidence-based recommendations for the management of knee 
OA have been issued in several treatment guidelines.12,24,25 For CO injections, the 
Osteoarthritis Research Society International 2014 treatment guidelines are consistent 
with the American College of Rheumatology’s 2012 guidelines suggesting that intra-
articular CO injections for patients in the absence of relevant comorbidities are 
appropriate because these treatments demonstrate clinically significant short-term 
decreases in pain.12,24 Nevertheless, this treatment is not suggested by the 2013 American 
Academy of Orthopaedic Surgeons guidelines, which cites inconclusive evidence to 
recommend the treatment use.25 Despite a large number of studies, the safety and efficacy 
of HA injections also remains inconclusive leading to a lack of consensus across clinical 
guidelines.12,24,25 
In addition to the conflicting recommendations from clinical guidelines, evidence 
about the extent to which long-term use of intra-articular injections improves patient 
outcomes is lacking. Recent systematic reviews and meta-analyses suggest that the effect 
of US-approved viscosupplement injections can last through 26 weeks but there is no 
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similar evidence for corticosteroid injections for persons with knee OA.17,26,27 Among 
patients with milder disease, receiving intra-articular sodium hyaluronate appears to slow 
joint space narrowing compared to placebo.28 For corticosteroid injections, there is no 
difference between treatment and placebo groups in joint space changes over two years of 
follow-up.29 Studies documenting the relationship between long-term use of intra-
articular injections and changes in symptoms using patient-reported outcomes on knee 
OA symptoms among general populations are scarce. Furthermore, no previous studies 
have evaluated treatment patterns for intra-articular injection use among patients with 
knee OA living in the community. 
 
Specific Aims 
This dissertation examined the effectiveness of commonly used intra-articular 
injections in relieving symptoms among persons with knee OA over 2 years using 
marginal structural models (MSMs). The use of advanced statistical techniques such as 
MSMs using inverse probability of treatment weights (IPTW) allowed us to quantify the 
effect of injections use over time in a more heterogeneous population than those typically 
recruited in clinical trials. In addition, it can also allow for improved adjustment of 
confounding in the situations where a special type of confounding (e.g., confounding by 
indication) that can occur when studying the effects of drugs using observational (non-
experimental) studies.30 However, when applying such a technique to estimate the effect 
of injection use on treating knee OA, we were required to fully understand the 
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complexity of treatment use over time as well as issues such as missing data approaches 
under the settings of MSMs. The specific aims of this dissertation were as follows. 
Aim 1. To evaluate longitudinal use of intra-articular injections after treatment initiation 
among persons with radiographic knee OA:   
In this aim, patterns of injection use among patients with newly initiated injection were 
described. Whether more severe OA symptoms after treatment initiation and/or changes 
in symptoms over time were associated with patterns of injection use was examined.  
Aim 2. To quantify the extent to which intra-articular injection relieves symptoms among 
persons with radiographic knee OA: 
In this aim, the effect of injection use patterns over a two-year period on changes in 
patient-reported symptoms was estimated in a real-world setting. 
Aim 3. To evaluate the performance of missing data techniques under the setting of 
MSMs: 
In this aim, simulated datasets under the plasmode simulation framework were generated. 
The bias and precision of estimates obtained from three missing data approaches in the 
setting of MSMs including complete case analysis (CC), multiple imputation (MI), and 
inverse probability weighting (IPW) were compared. 
 
Data Source and Study Population 
 This dissertation analyzed publicly available data from the Osteoarthritis Initiative 
(OAI) (http://oai.epi-ucsf.org/), a multi-center (i.e., Baltimore, MD; Columbus, OH; 
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Pittsburgh, PA; and Pawtucket, RI), longitudinal, prospective observational study 
examining not only the development and progression of knee OA but also the 
effectiveness of disease-modifying therapies. The study cohort included 4,796 men and 
women ages 45-79 enrolled between February 2004 and May 2006 and followed for 9 
years. Participants who have either symptomatic OA in at least one knee or have at least 
one from a set of established risk factors for developing knee OA such as having pain, 
aching, or stiffness in or around the knee, radiographic evidence of tibiofemoral 
osteophytes, the use of medications to treat for symptoms were eligible for the study. 
Detailed inclusion and exclusion criteria for the OAI are described elsewhere.31  
For this dissertation, 2,550 participants who had radiographic knee OA (Kellgren-
Lawrence (K-L) grade ≥ 2) at baseline served as the basis of the eligible sample for 
analyses. From this group, participants who reported already receiving injections at 
baseline, did not have any follow-up assessments, or were missing > half of follow-up 
assessments were excluded. From the remaining 2,150, we further excluded those 
reporting use of both injections, not reporting any injection use over the 9 years of 
follow-up, reporting first initiation at year 9, and reporting injections after total knee 
replacement. The final analytic sample for Aim 1 consisted of 412 participants initiating 
injection use. In addition to the new users selected for Aim 1, a group of participants not 
reporting any injection use over the 9 years of follow-up (non-user) was used in Aim 2. 
To mimic the study design from clinical trials,29,32 participants whose age < 45 years and 
did not have symptomatic knee OA at baseline were considered ineligible for injection 
use and thus further excluded for non-users. The final analytic sample included 412 
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participants initiating injection use and 576 non-users. Using the sample derived in Aim 
2, we used participants initiating CO injections and non-users to construct the cohort. 
Only complete cases that provided all of the information were used for generating 
simulated datasets. This resulted in a cohort consisting of 646 participants in Aim 3. 
 
Analytic Methods 
 A causal relationship between a treatment and its associated outcome becomes 
ambiguous in the presence of a confounder; the treatment effect is confounded when one 
or more risk factors for the outcome are also associated with the treatment. Observational 
studies, in which randomization cannot be performed like clinical trials, typically address 
confounding by applying statistical techniques such as stratification and multivariable 
regression analysis.  For a point treatment study in which the treatment is administered 
once, multivariable regression models may be sufficient to control for confounding.   
However, in longitudinal studies with repeated treatments over time, the estimates 
from regression models may still be biased if (1) there exists a time-dependent covariate 
that is a risk factor for, or predictor of, the event of interest and also predicts subsequent 
exposure, and (2) past exposure history predicts subsequent level of the covariate.30,33 In 
addition, condition (1) and (2) will always hold in many in pharmacoepidemiologic 
studies, particularly those in which there is confounding by indication and there are time-
dependent covariates that are simultaneously confounders and intermediate variables. For 
instance, it is often difficult to assess medical indications and underlying disease severity 
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and prognosis over time and thus confounding by indication may arise when a drug 
treatment appears to cause outcomes they are meant to prevent. 
 Traditionally, multivariable regression is used to account for differences in 
measured covariates between subjects. However, this method may not fully adjust for 
confounding by indication occurring if the health status of patients affects treatment 
allocation. Alternative analytic approaches such as propensity scores have been proposed 
that may provide more precise estimates of the treatment effect in observational studies in 
which confounding by indication may occur.34 Despite that propensity score-based 
analytic methods have been widely used in pharmacoepidemiologic studies, conditioning 
or stratification on time-dependent propensity score could induce substantial collider-
stratification or confounding bias when treatment and confounders vary during follow-
up.35  
 Another approach is instrumental variable analysis when substantial uncontrolled 
confounding is likely due to confounding by indication or confounding by disease 
severity.36 However, the primary barrier to the use of instrumental variable analysis is the 
need to have a plausible instrumental variable. Unfortunately, such variables have been 
difficult to find in epidemiology and medicine. Furthermore, inclusion of variables that 
are strongly related to the exposure, but unrelated to the outcome (i.e., instrumental 
variables), can increase the variance and bias of an estimated exposure effect when added 
to a statistical model. As such, any plausible instrumental variable could potentially 
introduce Z-bias in the presence of uncontrolled confounding.37,38 
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Marginal Structural Models 
In this dissertation work, since we sought to examine the complex relationship 
between the use of intra-articular injections (exposure) and changes in symptoms 
(outcome) over time using observational data, using traditional analytic methods to assess 
time-varying covariates and predictors will yield biased estimates especially when the 
time-varying confounders lie on the causal pathway between prior and subsequent 
exposures, and also affect the outcome measures.30 Marginal structural models (MSMs) 
are a class of causal models for the estimation, from observational data, of the causal 
effect of a time-dependent exposure in the presence of time-dependent covariates that 
may be simultaneously confounders and intermediate variables.30 As such, through 
applying IPTW, MSMs can allow us to account for changing values of the confounders 
over time and thus minimize the effect of confounding by indication that is compounded 
by the fact that treatment decisions may be affected not only by difference in baseline 
disease severity but by the natural course of the disease and by treatment response.  
MSMs has advantages of eliminating bias from two sources when estimating the 
effect from a time-varying treatment. First, through applying IPTW, it can control for the 
time-varying confounding while avoiding two types of bias that may arise in analyses 
with standard regression models.39 The first type of bias occurs when the time-varying 
confounder is simultaneously a confounder and intermediate variable. Conditioning 
analysis on such a variable (as performed in standard regression models) will block the 
indirect effect from previous treatment on study outcome that is mediated by this 
variable. Another type of bias (called collider-stratification bias33 or selection bias30) 
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occurs in standard regression models when the time-varying confounder is a common 
effect (i.e., a collider) of previous treatment and an unmeasured risk factor for the study 
outcome. Conditioning analysis on this time-varying confounder induces a non-causal 
relationship between previous treatment and the unmeasured risk factor, which introduces 
bias in the effect estimate of previous treatment use.30  
In addition the potential to minimize bias, using IPTW can provide several 
analytical advantages compared to propensity score methods. First, it requires fewer 
distributional assumptions about the underlying data. Second, it can avoid potential 
residual confounding arising from setting an arbitrary fixed number of strata. Last but not 
least, it uses entire sample and avoid losing people in the matching process. However, 
despite that weights created by IPTW can take on extreme values and thus affect the 
stability and precision of exposure effect estimates when the number of intervals 
increases, stabilization and truncation of weights can improve efficiency.40 
Before modeling the effect of injection use on knee OA, we used a causal diagram 
(Directed Acyclic Graph) to help identify potential confounders as well as methods to 
control for confounding over time (Figure 1.1). In this graph, Y(t) denotes outcomes 
(e.g., symptoms of knee) at visit t (e.g., 0, 1, 2,…t years) and L(t) corresponds to the 
measured time-varying confounders at visit t. L(t-1) includes the potential confounders 
available at baseline and covariates measured before injection initiation. 
As shown in Figure 1.1, previously measured study outcomes and time-varying 
confounders may be simultaneously confounders and intermediate variables. For 
instance, when studying knee OA symptoms as the outcomes (i.e., Y(t)), the severity of 
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symptoms measured at the previous visit (i.e., Y(t-1)) can be a potential confounder 
because 1) it correlates with symptoms measured at current visit, and 2) patients with 
more severe pain are more likely to use treatments (e.g., injection). Furthermore, if 
treatments are effective in relieving symptoms, previously measured symptoms (i.e., Y(t-
1)) lie on the causal path from prior treatment use and currently measured symptoms. 
Under such assumed causal relationships, using standard regression models adjusting for 
previous severity of symptoms will generate a biased estimate of the overall treatment 
effect of injection use on the outcome.41 In addition to the relationship between outcomes 
and potential confounders displayed in Figure 1.1, C(t+1) indicates censoring status 
during the follow-up periods which represents that analysis are only restricted to 
participants who have not been censored. 
 Since patients may change their treatment use and result in the loss to follow-up, 
we first evaluated whether factors such as OA symptoms after treatment initiation and/or 
changes in symptoms over time were associated with patterns of injection use among 
patients with knee OA in Aim 1. We first conducted descriptive statistics for continuous 
variables and percentages for categorical variables to describe socio-demographic and 
clinical characteristics according to patterns of injections use. Before starting the 
modeling process, we checked whether there were strong linear dependencies among the 
potential correlates. Multicollinearity was evaluated and ruled out before the model 
building process by evaluating the correlations between the covariates of interest. 
Multinomial logistic models were then built to evaluate the association between two 
operational expressions of exposure (symptoms post-initial injection; and change in 
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symptoms) and three symptoms (pain, stiffness, and physical function) for patterns of 
injection use. 
In Aim 2, we sought to quantify the extent to which intra-articular injection 
relieves symptoms among persons with radiographic knee OA. To properly control for 
the bias by time-varying confounders that may be affected by previous treatment, we 
used MSMs through applying IPTW estimation.42 IPTW reduces confounding through 
assigning a weight to each participant, which is proportional to the inverse of the 
conditional probability of receiving his/her observed treatment given those time-varying 
confounders.42 In the resulting weighted pseudo-population, treated participants and 
untreated participants are balanced over those time-varying confounders.42 Since the 
analysis is not conditioned on the confounders, IPTW can properly estimate overall 
treatment effect. 
The analytical approach for MSMs was conducted in three steps. First, each 
individual was weighted by the inverse of the conditional probability of receiving the 
treatment that was actually received to construct IPTW. This created a pseudo-population 
in which the differences in the distribution of confounders between those receiving the 
injection of interest and those not receiving were minimized. Stabilized weights were 
used to increase precision.30 The stabilized IPTW for each individual i at each visit t is: 
𝑆𝑊𝑖
𝑡(𝑡) = ∏
Pr⁡[𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖𝑡|𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖𝑡𝐶𝑂𝑁=𝑐𝑜𝑛𝑖𝑡]
Pr⁡[𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖𝑡|𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑖(𝑡−1)=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖(𝑡−1)𝐶𝑂𝑁=𝑐𝑜𝑛𝑖𝑡]
, where 
capital letters indicated a random variable, lowercase letters indicated the observed value 
for that random variable, and an over bar indicates the history of that variable until time 
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t.30 The IPTW was created using logistic models to estimate the probability of treatment 
for each individual with the covariates.30 
Second, the stabilized inverse probability of censoring weights (IPCW) was 
created in a similar fashion. Since bias can also arise from loss to follow-up when 
individuals discontinue study participation for reasons associated with predictors or 
confounders of interest, using stabilized IPCW can reduce bias due to censoring.30 The 
stabilized IPCW for each individual i at each visit t is: 𝑆𝑊𝑖
𝑡(𝑡) =
∏
Pr⁡[𝐶𝑡=0|?̅?𝑡−1=0,⁡⁡⁡𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑡−1𝐶𝑂𝑁,⁡⁡⁡𝑇>𝑡]
Pr⁡[𝐶𝑡=0|?̅?𝑡−1=0,⁡⁡⁡𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑡−1𝑇𝑉𝐶̅̅ ̅̅ ̅̅ (𝑡−1),⁡⁡⁡𝑇>𝑡]
, where C is a dichotomous variable (yes/no) 
indicating whether or not the participant has been censored at time t. Combined weights 
were then derived by multiplying the stabilized IPTW and IPCW. 
Lastly, weighted generalized estimating equation (GEE) linear models were fit. 
To determine the mean difference in changes in symptoms (Y), caused by the use of 
injections over time, weighted GEE models were used to fit linear models to assess the 
average causal effect of use of injections use on the difference in changes in symptoms. 
Robust variance estimators were obtained to address within-subject correlations induced 
by weighting. Model fit was assessed using Akaike’s Information Criterion (AIC) as well 
as regression diagnostics to identify potentially influential observations. 
 
Missing Data Approaches and Plasmode Simulation 
 Despite the advantages of MSMs using IPTW to estimate the unbiased causal 
effect when time-varying confounding is a concern,30,41,43 missing data of the covariate is 
another issue in longitudinal settings. The objective of Aim 3 was to compare validity 
 
 
15 
 
and precision obtained from commonly used missing data approaches (i.e., MI and IPW) 
through simulation studies in the presence of either missing time-independent or time-
varying confounders in cohort studies using MSMs. We simulated datasets under the 
framework of plasmode simulation using diagrams depicting causal relationship among 
the exposure (A), outcome (Y), covariates, and missing data mechanisms (Figure 1.2). 
While L0 indicates a set of all pre-specified confounders at baseline, Lt represents time-
dependent confounders measured at time t. C’ indicates a set of potential confounders in 
addition to the pre-specified confounders that are selected in the data generating 
mechanism. Some arrows are omitted due to the simplicity for presentation. Missing data 
mechanisms including missing completely at random (MCAR), missing at random 
(MAR), and missing not at random (MNAR) are represented by M. 
Overall, the analytic approach for Aim 3 was carried out in three steps. First, we 
used the plasmode simulation frame work to create simulated data sets.44 We began by 
constructing the cohort using the study sample in Aim 2 which included complete cases 
of participants initiating CO injections and non-users. We then estimated a linear 
regression model for the observed study outcome as a function of the exposure status, 
baseline covariates, and a subset of the potential confounders. This estimated model 
served as the basis of outcome-generating model. Next, to create a simulated data set, we 
sampled with replacement among exposed and unexposed participants from the 
constructed cohort to achieve the desired sample size. Since we preserved the information 
on covariates and exposure data for each participant without modification, associations 
among these variables remained intact in the sampled population. We then used the 
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outcome-generating model described above to generate outcome values through replacing 
a pre-identified treatment effect on the estimated coefficient exposure. The value of all 
other model coefficients remained unchanged and was used to generate values of 
outcome status for each patient in the simulated data. This process was repeated 1000 
times to yield 1000 simulated data sets in each simulation scenario. 
Second, we introduced missing data mechanisms and scenarios to the simulated 
data sets. The missing data mechanisms missing completely at random (MCAR), missing 
at random (MAR), and missing not at random (MNAR) were used.45,46 Missing data is 
considered as MCAR when the probability of missing does not depend on the values of 
observed covariates. If the probability of missing depends on values of observed 
covariates, it is considered as MAR. If it is informative, MNAR is considered when the 
probability of missing depends on values of unobserved covariates. In this study, we 
assumed that participants with more severe knee OA status (for the time-independent 
confounder) and higher knee pain (for the time-dependent confounder) were more likely 
to be missing using the empirical data. 
In addition to complete case analysis, we then applied IPW and MI to take into 
account the missing data in the analysis. In the setting of MSMs, IPW is not a new 
approach for handling missing data and is particularly straightforward to use.47,48 It is 
similar to the weight building process for the inverse probability of observed treatment or 
censoring weights that are performed under MSMs.30 IPW proceeds by calculating the 
probability of having complete data for each individual in the study. Using logistic 
regression models, each individual is weighted by the inverse probability of having 
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complete data conditional on other relevant covariates. In MI, on the other hand, missing 
values in the incomplete observed data are actually imputed through generating m 
complete datasets. Each of the imputed datasets is then analyzed using the same outcome 
model or method of estimation. Estimates from each of the imputed datasets are then 
combined to produce a single estimate that incorporates the sampling variability as well 
as the variability of the missing data.49 
Lastly, weighted GEE linear models were fit using CC, IPW and MI to estimate 
the average causal effect in MSMs over increasingly problematic scenarios of 
missingness. Performance of methods was compared using relative bias, mean squared 
error, and empirical power of the estimates of interest. 
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Figure 1.1: Directed acyclic graph (causal diagram) between the initiation of treatment 
use, study outcomes, censoring, and potential time-varying confounders. 
 
 
 
 
 
 
 
 
 
 
 
 
LEGEND: Hypothesized causal relationships between treatment use, study outcomes 
and potential time-varying confounders. Y(t) denotes outcomes at visit t (e.g., 0, 1, 
2,…t years) and L(t) corresponds to the measured time-varying confounders at visit t. 
L(t-1) includes the potential confounders available at baseline and covariates measured 
before injection initiation Y(t)). C(t+1) indicates censoring status during the follow-up 
periods which represents that analysis are only restricted to participants who have not 
been censored. 
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Figure 1.2: Causal diagrams depicting relationship in simulated datasets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LEGEND: Data generation and missing mechanisms for simulation studies.  L0 
indicates a set of all pre-specified confounders measured at baseline, Lt represents 
time-varying confounders of the exposure (A) and outcome (Y) association measured 
at time t.  C’ indicates a set of potential confounders in addition to the pre-specified 
confounders that are selected in the data generating mechanism.  M indicates missing 
mechanisms.  A) This causal diagram shows that missingness (M) is present in the 
baseline confounder L0; B) This causal diagram shows missingness (M) in the time-
varying confounder Lt;; and C) This causal diagram indicates that missingess (M) is 
present in either or both baseline or time-varying confounders. 
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CHAPTER II 
PATTERNS OF INTRA-ARTICULAR INJECTION USE AFTER INITIATION 
OF TREATMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS: DATA 
FROM THE OSTEOARTHRITIS INITIATIVE 
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Abstract 
Objective: We sought to describe and evaluate longitudinal use of intra-articular 
injections after treatment initiation among adults with radiographically confirmed knee 
osteoarthritis (OA). 
Methods: Using data from the Osteoarthritis Initiative, we included participants with 
radiographically confirmed OA (Kellgren-Lawrence grade (K-L) ≥ 2) in ≥ 1 knee at 
baseline.  With 9 years of follow-up data, 412 participants newly initiating hyaluronic 
acid or corticosteroid injections at their index visit were identified.  For each type of 
injection initiated, socio-demographic and clinical characteristics were described by 
patterns of treatments (one-time use, switched, or continued injections).  Multinomial 
logistic models estimated the extent to which patient-reported symptoms (post-initial 
injection and changes over time) were associated with patterns of injection use. 
Results: Of those initiating injections, ~19% switched, ~21% continued injection type, 
and ~60% did not report any additional injections.  For participants initiating 
corticosteroid injections, greater symptoms post-initial injection were associated with 
lower odds of continued use compared to one-time users (adjusted odds ratio (aOR) for 
WOMAC pain: 0.91; 95%, confidence interval (CI): 0.83 to 0.99; aORstiffness: 0.77; CI: 
0.63 to 0.94; aORphysical function: 0.97; CI: 0.94 to 1.00).  Symptom changes over time (e.g., 
worsened or improved) were not associated with patterns of injections use. 
Conclusions: After treatment initiation, the proportion of patients switching injection use 
and one-time users was substantial.  Symptoms post-initial injection rather than changes 
in symptoms over time appear to be associated with patterns of injection use.  The extent 
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to which these patterns are an indication of lack of impact on patient-reported symptoms 
should be explored. 
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Introduction 
Osteoarthritis (OA) is the most commonly seen arthritis among U.S. adults.11,50,51 
Among OA-affected joints, knee OA is one of the leading causes of disability among 
adults living in the community.11 OA is a slowly progressive joint disease and currently 
has no cure. Generally, the treatment goals for non-pharmacologic or pharmacologic 
treatment of OA include pain relief, improved mobility, delayed disease progression, and 
improved quality of life. For those whose non-pharmacologic interventions or symptom-
relieving medications are ineffective, intra-articular injections may be recommended to 
attempt to more directly target underlying pathophysiological processes.12–14,52 
Although several guidelines for the treatment of knee OA have been issued, the 
recommendations for use of intra-articular injections such as corticosteroid or hyaluronic 
acid injections are inconsistent.12,24,25 Costs contributing to the long-term use of injections 
due to the chronic symptoms of knee OA could be substantial.53 Intra-articular injections 
are increasingly common, particularly among patients newly diagnosed with knee OA.54 
Given the concern regarding increase in use and the associated economic burden for 
patients with knee OA, evaluating how patients use these modalities over time is 
important. Examining patterns of injections use can help understand the switching and/or 
augmentation of treatment related to clinical outcomes.55,56 However, no previous studies 
have evaluated treatment patterns for intra-articular injection use among patients with 
knee OA living in the community. 
This study sought 1) to describe and evaluate longitudinal use of intra-articular 
injections after treatment initiation; and 2) to identify factors associated with patterns of 
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treatment use among adults with radiographically confirmed knee OA. With the data 
derived from yearly visits from the Osteoarthritis Initiative (OAI), we were able to 
identify newly initiated injection users and examine factors associated with treatment 
patterns. We hypothesized that the patterns of injection use among participants initiating 
injections would be associated with more severe OA symptoms and/or changes in 
symptoms over time compared to those received one-time injections. 
 
Methods 
Study sample 
Publicly available data from the OAI were used.31 The OAI study was originally a 
prospective cohort which enrolled participants from Baltimore, MD; Columbus, OH; 
Pittsburgh, PA; and Pawtucket, RI from 2004 through 2006. Using these four study sites, 
4,796 patients with established knee OA or at high risk for developing knee OA were 
enrolled. For this present retrospective cohort study, we used information from annual 
assessments from baseline through year 9. Figure 2.1 shows the study sample for the 
current study. We first included patients with radiographically confirmed knee OA 
(defined as having a Kellgren-Lawrence grade (K-L) >2) at baseline (n=2,550). From this 
group, participants who reported already receiving injections (corticosteroid or 
hyaluronic) at baseline (n=97) were excluded.  In addition, participants with no follow-up 
assessments or missing > half of these assessments were also excluded (n=303). From the 
remaining 2,150, we further excluded those reporting use of both injections (concurrent 
users, n=52), not reporting any injection use over the 9 years of follow-up (n=1,636), 
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reporting first initiation at year 9 (n=47), and reporting injections after total knee 
replacement (n=3). The final analytic sample consisted 412 participants initiating 
injection use. 
 
Index Knee for Analysis 
 In OAI, symptoms and x-rays for both knees were collected separately. We 
selected an index knee for use in the analysis based on the presence of symptoms (knee 
pain) and radiographic evidence of OA. For participants with only one radiographically 
confirmed OA knee at baseline, that knee was used as the index knee. If both knees were 
radiographically confirmed with OA, then the knee with greater pain at baseline 
measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
pain scale was used. If both pain scores were equal, then the knee with worse K-L grade 
was used as the index knee. 
 
Injections use, index visit, and patterns defined 
Injection use was assessed separately for both knees in OAI. Participants were 
first asked “During the past 6 months, have you had any injections in either of your knees 
for treatment of arthritis?” For those who answered yes, participants were then asked 
questions “During the past 6 months, have you had an injection of hyaluronic acid 
(Synvisc or Hyalgan) in either of your knees for treatment of your arthritis? These 
injections are given as a series of 3 to 5 weekly injections.” To assess corticosteroid 
injections, participants were asked: “During the past 6 months, have you had an injection 
 
 
26 
 
of steroids (cortisone, corticosteroids) in either of your knees for treatment of your 
arthritis?” The visit that participants reported their initial injection was used as the index 
visit. 
After identifying the initial injection and index visit, switching injection users 
were then defined as reporting at least one injection other than their initial injection 
during follow-up. For example, for participants who initiated corticosteroid injection use, 
reporting a hyaluronic acid injection constituted a switch. Continued users were defined 
as reporting more than one injection of the same type during follow-up. Those who did 
not report either a switching or continuing use during follow-up were considered as one-
time injection users. To determine the first switching/continued injection use among one-
time users, we matched by the distribution of follow-up time intervals between injection 
initiations and first reported switching/continuation among those switched and continued 
users. 
 
Symptoms   
In the OAI, knee-related symptoms such as pain, stiffness, and physical function 
were examined annually using WOMAC, with a 5-point Likert scale.  The range of 
scores was 0 to 20 for pain, 0 to 8 for stiffness, and 0 to 68 for physical function.57 For 
each subscale, higher numbers indicated worse symptoms. We were interested in 
evaluating patient-reported symptoms in two ways: 1) symptoms post-initial injection; 
and 2) longitudinal change in symptoms. We believed that these two metrics offered 
complementary (but distinct) information. While we considered that higher symptoms 
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post-initial injection represent a surrogate for chronic and persistent symptoms of the 
knee,58–60 we also evaluated change in symptoms over the disease course which could 
also be associated with treatment use. 
Symptoms post-initial injection were measured at the index visit in which the 
initial injection was reported. Change in symptoms were assessed from the index visit to 
the visit before the reported switching/continued injection use. To evaluate average 
changes of symptoms between visits, we had to account for the varied number of years 
between visits. To do so, the difference of symptoms between index visit of injections use 
and one visit before the visit reporting switched/continued injection use was first 
calculated and then divided by the appropriate time intervals (Figure 2.2.A). For example, 
if the participants reported an initial injection at visit 2 and reported switching/continued 
injection use at visit 5, the average change of symptoms (e.g., WOMAC pain) between 
visits was calculated as: (pain score (visit 4) – pain score (visit 2)) / 2. If participants 
initiated injections use at visit 2 and reported switching/continued injection use at one 
year after initiation at visit 3, the difference between the index visit and one year before 
was calculated (Figure 2.2.B). Using these change scores adjusted for time intervals, we 
created 3 categories to define minimal clinically important changes for each symptom: 1) 
improved, 2) no change, and 3) worsened. A negative change in WOMAC scores 
indicated improvement ranging from -4.6 to -1.2 for pain, -1.5 to -0.5 for stiffness, and -
9.9 to -4.1 for physical function.61–64 The minimal threshold was used for creating the 
categories (e.g., improved pain was defined as < -1.2; worsened pain was defined as > 
1.2; and no change was defined as -1.2 to 1.2). 
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Covariates 
 Sociodemographic characteristics including age, sex, race/ethnicity, income, and 
education were evaluated. Clinical characteristics such disease severity, knee-related 
symptoms, insurance coverage, general health status, and physical activity were also 
assessed. Sociodemographic variables (e.g., sex, race/ethnicity, and household income) 
were considered time-invariant variables and thus using information from the enrollment.  
Information from the index visit were used for other variables. 
 Sociodemographic variables were self-reported. Race/ethnicity was categorized as 
non-Hispanic White, non-Hispanic Black, and other. Educational levels were collapsed 
and categorized as high school or less, some college, college graduate, and at least some 
graduate school. Annual household income was categorized into three levels: < $25,000, 
$25,000-50,000, and > $50,000. 
 Clinical characteristics such as disease severity was measured based on K-L grade 
and joint space width (JSW). A detailed protocol regarding the measurement of JSW has 
been documented elsewhere.31,65 If JSW measures were implausible (e.g., the distance 
between plateau and rim was > 6.5mm), we treated these as missing as these measures 
could be due to poorly positioned knees.31 Multi-joint symptoms were present if 
participants had frequent pain, aching, or stiffness in ≥ two joints other than knee.  
Cumulative measures were used to assess the history of knee injury and surgery. 
Information was collected on prior knee injuries if participants had limited ability to walk 
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for ≥ two days reported at any previous visit. A history of having knee surgery included 
arthroscopy, ligament repair or meniscectomy at any previous visit. 
 General health status was evaluated using the 12-item Short-Form Health 
Survey (SF-12),66 with summary scores for physical and mental health ranging from 0 to 
100 and higher scores indicating better health status. Body mass index (BMI) was 
calculated using measured height and weight [weight (kg)/height (m)2]. Participants were 
categorized into: < 25, normal weight; 25 to < 30, overweight; and ≥ 30, obese.67  
Information on depressive symptoms were collected using Centers for Epidemiologic 
Studies Depression Scale (CES-D). A CES-D score >16 indicated elevated depressive 
symptoms.68 Comorbidity status was evaluated using the Charlson index and then 
categorized into 0, 1, and ≥ 2.69 Health coverage status and physical activity were self-
reported. The Physical Activity Scale for the Elderly (PASE) consisting of 26 items was 
used to assess activities including occupational, household, and leisure work over the past 
week, with higher scores indicating greater activities.70 
 
Statistical analyses 
 Descriptive statistics including means and standard deviations (SD) for 
continuous variables and percentages for categorical variables were first calculated to 
describe socio-demographic and clinical characteristics by patterns of injections use for 
types of injections initiated at the index visit. Average yearly changes in symptoms 
between treatment initiation and switching/continued treatment use were also examined. 
Multicollinearity was evaluated and ruled out before the model building process by 
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evaluating the correlations between the covariates of interest. Six multinomial logistic 
models were then built to evaluate the association between two operational expressions 
(symptoms post-initial injection; and change in symptoms) for three symptoms (pain, 
stiffness, and physical function) with patterns of injection use. Adjusted odds ratios 
(aOR) and 95% confidence intervals (CI) for each group compared to a common 
reference group (one-time users) were estimated after adjusting for socio-demographics 
and clinical/functional factors. Due to the small sample size, we were not able to examine 
such relationships among participants initiating hyaluronic acid use.  To address the 
possibility of misclassification bias, and specifically the case that those classified as “not 
continued” users may include patients who went on to total knee replacement (TKR) 
during the follow-up, we also conducted a sensitivity analysis.  We first examined the 
overall proportion of participants who received TKR in follow-up among the group who 
were classified as not continued users.  We then repeated the analysis and compared the 
findings with the main analysis after removing those participants who were initially 
classified as “not continued” but had TKR during follow-up. 
  
Results 
Overall, 96 initiated of hyaluronic acid injections and 316 initiated corticosteroid 
injections. Regardless of the type of initial injection, nearly 1 in 5 participants switched 
or continued the initial injection use and approximately 60% of participants did not 
receive any additional injections. Socio-demographic and clinical characteristics of 
participants initiating hyaluronic acid injections are presented in Table 2.1. The average 
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age of those who switched from hyaluronic injections to corticosteroids was 62.0 years 
whereas the average age for those continuing with hyaluronic injections or who had only 
one injection was 65.6 years and 67.0 years, respectively. Fifty-two percent of those who 
switched injections were women, while 40.0% of those who continued and 46.6% of one-
time users were women. Nearly two thirds of continued users and one-time users had at 
least some graduate school education whereas half of those switching injections use had 
graduate level education. Half of participants who switched injections had K-L grade 4 
and reports of multi-joint symptoms and history of knee injuries were common. Mean 
WOMAC pain at the index visit was 5.8 (SD: 3.7) for switching users whereas those who 
continued use and one-time users were 4.0 (SD: 2.9) and 6.3 (SD: 3.7), respectively. 
For participants initiating corticosteroid injections (Table 2.2), the average age of 
one-time users was 68.7 years (SD: 9.5 years) whereas those switched or continued were 
67.2 years and 67 years of age, respectively. The majority of participants initiating 
corticosteroid injections had annual household income >$50,000. For clinical 
characteristics, nearly half of participants who switched injection use had K-L grade 2 
relative to the other groups (e.g., continued: 38.6%, one-time users: 30.2%). Overall, the 
majority of participants initiating corticosteroid injections had multi-joint symptoms. 
Knee-specific symptoms such as mean WOMAC pain at the index visit was 7.0 (SD: 4.4) 
for switching users whereas those who continued and one-time users were 5.2 (SD: 4.0) 
and 6.3 (SD: 4.1), respectively. 
 Table 2.3 shows the association between symptoms post-initial injection and 
switching or continuing corticosteroid injections compared to one-time users. In relation 
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to one-time users, greater knee-specific symptoms post-initial injection were associated 
with lower odds of continued injections use (adjusted odds ratio (aOR) for WOMAC 
pain: 0.91; 95%, confidence interval (CI): 0.83 to 0.99; aORstiffness: 0.77; CI: 0.63 to 0.94; 
aORphysical function: 0.97; CI: 0.94 to 1.00). Compared with one-time users, symptoms post-
initial injection and changes in symptoms over time did not appear to be associated with 
switching injections use among initiators of corticosteroid injections. 
Table 2.4 shows the association between the clinically relevant change in 
symptoms with first switching/continuation compared to one-time users among 
participants initiating corticosteroid injections use. Reaching a priori defined minimally 
clinical important differences in worsened or improved pain was not associated with 
patterns of switching or continued injections use compared to one-time users.  No 
association was observed for stiffness and physical function. 
To address the possibility of misclassification bias in specification of “not 
continued” users, we found that approximately 8.5% of participants in this group had 
TKR after the initiation of injection use. After excluding those participants, results were 
comparable to the main findings.  
Discussion 
 To our knowledge, this present study is the first study to describe the patterns of 
intra-articular injection use in patients with knee OA. Our data suggest that a substantial 
proportion of knee OA patients initiating intra-articular injections switched their 
treatment or used it for one time, regardless of the initial therapy or actual symptoms 
change. We found that approximately 1 in 5 participants initiating injections had 
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switched injection type, but that channeling into the hyaluronic injections was not 
apparent. While 24.0% of hyaluronic acid initiators switched to corticosteroid injections, 
17.8% of corticosteroid initiators switched to hyaluronic acid injections. We also 
observed that it was reported symptoms post-initial injection rather than changes in 
symptoms (e.g., improved or worsened) over time that appeared to be associated with 
patterns of use among corticosteroid users.   
 We hypothesized that the patterns of injection use among persons with knee OA 
would be associated with more severe symptoms and/or changes in symptoms over time 
compared to those who only received one-time injections. Although we were not able to 
examine such a relationship among participants initiating hyaluronic acid injections 
owing to a limited sample size available for analysis, our findings did support the 
hypothesis that greater symptoms post-initial injection were associated with lower odds 
of continued treatment use among participants initiating corticosteroid injections. Further, 
we observed that changes in knee symptoms over time were not associated with either 
switching or continued injections compared to one-time users. Several explanations could 
be responsible for this observation.  It might be the channeling effects of injection use 
rather than the actual symptom changes since current clinical guidelines are still 
conflicting.12,24,25,71,72 A similar phenomenon was found in a study of celecoxib compared 
to other NSAIDs in OA patients.73 Another potential explanation is that the relation 
between change in symptoms and actual treatments received may not be a linear. As 
such, it may affect the treatment decisions, particularly in persons with OA.58,59 Since the 
sensitization of symptoms could be both influenced by both physical and psychological 
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factors, it could be that sustained chronic symptoms rather than the success or failure of 
treatment affect treatment decisions. 
In addition to symptoms of the knee, the decision to continue or switch intra-
articular injections among patients might be driven by several factors including patient 
choice, physician specialty, insurance reimbursement, and cost .74,75 Indeed, the cost to 
manage OA could be substantial.76–78 Typically, patients switch from cheaper treatments 
(e.g., corticosteroid injections) to newer and more expensive therapies that may target 
more directly the underlying pathophysiological effects (e.g., hyaluronic acid injections). 
However, we observed that approximately 1 in 4 participants initiating hyaluronic acid 
injection use switched to corticosteroid injections. Currently, treatment guidelines for 
patients with knee OA do not suggest a “step-up” approach for intra-articular injections 
use compared to other pain treatments, such as NSAIDs.12,24,25 Another factor could be 
that “clinical equipoise” still exists and physicians and patients frequently switch between 
available options.79,80 The end result may be additional economic and human burden of 
OA. Although general practitioners can administer corticosteroid injections, hyaluronic 
acid injections are typically provided by specialists such as an orthopedic surgeons or 
rheumatologists. The extent of switching from hyaluronic injections to corticosteroid 
injections observed in this study may be a reflection of ease of convenience, rather than 
preference of injection type.75 
Treatment switching, continuation, and discontinuation in populations with 
chronic disease might be due to suboptimal efficacy, safety, and tolerability of treatment 
modalities.55,56 We did observe that there were high percentages of switching in both 
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groups and this could be due to patients’ attempts to manage chronic pain with potentially 
suboptimal treatments. Indeed, recent evidence shows that viscosupplements can last 
through 26 weeks but no similar evidence exists for corticosteroid injections among 
persons with knee OA.26,27 More studies regarding the long-term efficacy using multiple 
treatments might be needed. We observed a high proportion of one-time injection use in 
this study. While in some clinical scenarios this may indicate potentially intolerable side 
effects of the modalities, adverse events and side effects of intra-articular injections are 
rare and more often due to localized reactions (e.g., swelling or redness on the injection 
site) rather than systematic effects from the agent.81 In this present study, we were not 
able to evaluate this relationship since information related to adverse effects is limited in 
the OAI. The high proportion of one-time use may also be reflective of lack of perceived 
efficacy of the treatment.82 
Strengths and limitations of this study are acknowledged. This is the first study 
examining patterns of intra-articular injections use for patients with knee OA. Although 
participants were not newly diagnosed with OA and thus may have had injection use 
before entering into the study, a new user design was used to minimize the bias.83 Using 
data from the OAI, we were able to evaluate the associations between clinical outcomes 
and patterns of injections use longitudinally. The low number of participants initiating 
hyaluronic acid injections limited our ability to develop models of patterns of injection 
use in this group. Despite the comprehensive assessment in OAI, physicians’ prescribing 
notes or chart information are lacking. Therefore, the extent to which treatment switching 
and continued use observed in this study related to safety or tolerability of injections use 
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is unknown. Although the indication of injections was self-reported and assessed for the 6 
months before annual visits in the study, the proportion of participants receiving either 
injections is comparable to previous study.84 In addition, there is a potential for mismatch 
between the timing of actual injection use and assessments of symptoms. We may not 
have the optimal window to examine the associations of injection use and symptoms for 
all participants. However, we examined symptoms using two operational definitions 
which provided complementary but distinct information. Last, since those “not 
continued” users may include patients who went on to TKR, there is a potential for 
misclassification bias.  However, results from sensitivity analysis were comparable to the 
main findings.  
In conclusion, we found that approximately 19% of patients with radiographically 
confirmed knee OA who initiated injections switched injection type and ~60% did not 
receive any injections after their initial injection. Furthermore, among those initiating 
corticosteroid injection use, we also observed that it was the symptoms post-initial 
injection rather than changes in symptoms (e.g., improved or worsened) over time that 
might be associated with patterns of injections use. Despite that the proportion of patients 
switching injection use and one-time users was substantial in both types of commonly 
used treatment agents, there is currently no “step-up” approach for intra-articular 
injections use in treatment guidelines for patients with knee OA. Further, these 
phenomena may suggest that longer-term efficacy regarding symptom relief and/or 
slowing disease progression of these agents may be suboptimal among patients with OA 
in the real-world setting.  
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Figure 2.1: Flowchart of study participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OAI participants: n=4,796  
Participants with radiographic knee OA: 
n=2,550 
Non-users of corticosteroid / hyaluronic acid 
injections with clinical and radiographic knee 
OA at baseline: n=2,150 
Exclusions:  
(1) 97 had use of corticosteroid / hyaluronic acid 
injections at baseline 
(2) 303 had no or missing more than half of follow-
up visits 
 
n=412 users: 
(1) 96 had hyaluronic acid injections 
(2) 316 had corticosteroid injection 
Exclusions: 
(1) 52 concurrent users 
(2) 1,636 non-users over the 9 years of follow-up 
(3) 47 with first initiation at year 9 
(4) 3 had injections after total knee replacement 
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Δ 
Figure 2.2: Scheme of the study design to define changes between visits among injection users.  
Visit 2 
Average Δ 
Visit 3 Visit 4 Visit 5 Visit 1 
(A) 
(B) 
Δ : the annual change in symptoms or function 
CO: corticosteroid; HA: hyaluronic acid 
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Table 2.1: Clinical characteristics by patterns of hyaluronic acid injection use (N=96*). 
Characteristics 
Switching users 
(n=23) 
Continued users  
(n=15) 
One-time users 
(n=58) 
Mean (SD) age in years 62.0 (8.0) 65.6 (7.4) 67.0 (8.6) 
Mean (SD) intervals of visit 2.4 (1.9) 1.5 (0.9) NA 
Women (%)a 52.2 40.0 46.6 
Race/ethnicity (%)a    
Non-Hispanic White 82.6 93.3 89.7 
Non-Hispanic Black 8.7 0 6.9 
Other 8.7 6.7 3.5 
Education (%)a    
High school or less 8.7 20.0 12.3 
Some college 39.1 20.0 22.8 
College graduate 8.7 33.3 19.3 
Some graduate school or above 43.5 26.7 45.6 
Income (%)a    
<$25,000 0 13.3 3.5 
$25,000 - $50,000 34.8 6.7 22.8 
>$50,000 65.2 80.0 73.7 
Body mass index (%)    
Normal 13.0 20.0 15.5 
Overweight 34.8 20.0 31.0 
Obese 52.2 60.0 53.5 
Health care coverage (%) 100.0 100.0 100.0 
Kellgren-Lawrence grade (%)    
2 15.0 15.4 18.4 
3 35.0 46.2 46.9 
4 50.0 38.5 34.7 
Multi-joint symptoms (%) 78.3 46.7 60.3 
History of knee injury (%) 69.6 46.7 56.9 
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History of knee surgery (%) 56.5 46.7 53.5 
Depressive symptoms (CES-D >16) 
(%) 
13.0 20.0 9.3 
Comorbidity status (%)    
0 73.9 64.3 72.4 
1 17.4 28.6 19.0 
≥2 8.7 7.1 8.6 
WOMAC scores, mean (SD)    
Pain 5.8 (3.7) 4.0 (2.9) 6.3 (3.7) 
Stiffness 2.7 (1.7) 2.3 (1.5) 3.0 (1.6) 
Physical function 17.1 (11.5) 14.2 (9.9) 18.7 (12.1) 
Joint space width, mean (SD) 3.4 (1.9) 4.6 (1.7) 3.9 (2.2) 
SF-12 PCS, mean (SD) 40.2 (9.9) 41.5 (9.1) 41.2 (10.4) 
SF-12 MCS, mean (SD) 54.0 (7.6) 53.5 (11.5) 56.2 (7.6) 
PACE, mean (SD) 154.2 (70.4) 177.4 (64.2) 145.1 (82.3) 
Abbreviation: CES-D, Centers for Epidemiologic Studies Depression Scale; MCS, SF-12 Mental Component Summary scores; 
PACE, Physical Activity Scale for the Elderly; PCS, SF-12 Physical Component Summary scores; SD, standard deviation; 
WOMAC, The Western Ontario and McMaster Universities Arthritis Index. 
a Information at enrollment was used. 
* Number of participants with missing information: education (1), annual household income (1), health care coverage (5), 
Kellgren-Lawrence grade (14), CES-D (4), comorbidity status (1), WOMAC Physical function (2), joint space width (24), SF-
12 PCS (5), SF-12 MCS (5), PACE (2). 
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Table 2.2: Clinical characteristics by patterns of corticosteroid injection use (N=316*). 
Characteristics 
Switching users 
(n=56) 
Continued users  
(n=75) 
One-time users 
(n=185) 
Mean (SD) age in years 67.2 (9.5) 67.0 (7.9) 68.7 (9.5) 
Mean intervals 2.3 (1.7) 1.9 (1.5) NA 
Women (%)a 66.1 60.0 64.3 
Race/ethnicity (%)a    
Non-Hispanic White 76.8 74.7 78.4 
Non-Hispanic Black 14.3 20.0 18.4 
Other 8.9 5.3 3.2 
Education (%)a    
High school or less 14.3 14.7 21.7 
Some college 21.4 26.7 27.7 
College graduate 28.6 24.0 20.1 
Some graduate school or above 35.7 34.7 30.4 
Income (%)a    
<$25,000 14.3 12.0 15.8 
$25,000 - $50,000 28.6 28.0 33.7 
>$50,000 57.1 60.0 50.5 
Body mass index (%)    
Normal 14.3 12.0 13.0 
Overweight 33.9 45.3 41.1 
Obese 51.8 42.7 46.0 
Health care coverage (%) 100.0 100.0 98.9 
Kellgren-Lawrence grade (%)    
2 48.9 38.6 30.2 
3 28.9 38.6 39.0 
4 22.2 22.9 30.8 
Multi-joint symptoms (%) 66.1 58.7 51.9 
History of knee injury (%) 42.9 49.3 51.4 
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History of knee surgery (%) 23.2 32.0 37.3 
Depressive symptoms (CES-D >16) 
(%) 
18.2 13.3 14.0 
Comorbidity status    
0 52.7 58.7 65.8 
1 32.7 24.0 15.2 
≥2 14.6 17.3 19.0 
WOMAC scores, mean (SD)    
Pain 7.0 (4.4) 5.2 (4.0) 6.3 (4.1) 
Stiffness 3.0 (1.8) 2.5 (1.8) 2.9 (1.7) 
Physical function 20.2 (12.7) 17.2 (13.6) 19.6 (13.2) 
Joint space width, mean (SD) 4.7 (1.9) 4.4 (2.0) 4.2 (1.9) 
SF-12 PCS, mean (SD) 39.4 (8.7) 41.1 (10.3) 41.3 (9.9) 
SF-12 MCS, mean (SD) 54.8 (10.4) 55.1 (9.5) 53.8 (9.3) 
PACE, mean (SD) 141.0 (81.0) 137.9 (71.8) 137.3 (73.8) 
Abbreviation: CES-D, Centers for Epidemiologic Studies Depression Scale; MCS, SF-12 Mental Component Summary scores; 
PACE, Physical activity scale for the elderly; PCS, SF-12 Physical Component Summary scores; SD, standard deviation; 
WOMAC, The Western Ontario and McMaster Universities Arthritis Index. 
a Information at enrollment was used. 
* Number of participants with missing information: education (1), annual household income (1), health care coverage (10), 
Kellgren-Lawrence grade (42), CES-D (7), comorbidity status (2), WOMAC Physical function (7), joint space width (94), SF-
12 PCS (16), SF-12 MCS (16), PACE (20). 
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Table 2.3: Association* between symptoms post-initial injection and first switching/continuation of corticosteroid injections 
among participants with radiographic confirmed knee osteoarthritis. 
 Switching users Continued users 
Pain Odds Ratio (95% Confidence Interval) 
Crude  1.04 (0.97 to 1.12) 0.93 (0.87 to 1.00) 
Adjusteda 0.97 (0.88 to 1.07) 0.91 (0.83 to 0.99) 
Stiffness   
Crude  1.02 (0.86 to 1.21) 0.88 (0.75 to 1.03) 
Adjusteda 0.83 (0.66 to 1.05) 0.77 (0.63 to 0.94) 
Physical function   
Crude  1.00 (0.98 to 1.03) 0.99 (0.97 to 1.01) 
Adjusteda 0.97 (0.94 to 1.00) 0.97 (0.94 to 1.00) 
* Odds ratios (95% Confidence Intervals) were estimated using participants with one-time use of injections as the reference 
group. 
a Adjusted for age at the index visit, sex, K-L grade, comorbidity status, and SF-12 physical component scores. 
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Table 2.4: Association* between average change in symptoms and first switching/continuation of corticosteroid injections 
among participants with radiographic confirmed knee osteoarthritis. 
 Switching Continued 
Pain Improved 
Pain¶ 
No changes Worsened 
Pain 
Improved 
Pain¶ 
No changes Worsened 
Pain 
Crude 0.69  
(0.32 to 1.49) 
Reference 1.11  
(0.54 to 2.31) 
0.48  
(0.24 to 0.99) 
Reference 1.00  
(0.52 to 1.89) 
Adjusteda 0.61  
(0.25 to 1.47) 
Reference 0.66  
(0.27 to 1.61) 
0.56  
(0.26 to 1.22) 
Reference 0.99  
(0.49 to 2.01) 
Stiffness Improved 
Stiffness¶ 
No changes Worsened 
Stiffness 
Improved 
Stiffness¶ 
No changes Worsened 
Stiffness 
Crude 0.96  
(0.46 to 2.00) 
Reference 0.66  
(0.31 to 1.43) 
1.39  
(0.70 to 2.78) 
Reference 1.19  
(0.59 to 2.38) 
Adjusteda 1.02  
(0.44 to 2.33) 
Reference 0.47  
(0.18 to 1.19) 
1.53  
(0.72 to 3.24) 
Reference 1.34  
(0.64 to 2.82) 
Physical function Improved 
Function¶ 
No changes Worsened 
Function 
Improved 
Function¶ 
No changes Worsened 
Function 
Crude 0.57  
(0.26 to 1.23) 
Reference 0.63  
(0.30 to 1.31) 
0.58  
(0.29 to 1.15) 
Reference 0.58  
(0.30 to 1.12) 
Adjusteda 0.55  
(0.23 to 1.33) 
Reference 0.42  
(0.17 to 1.05) 
0.71  
(0.34 to 1.49) 
Reference 0.68  
(0.33 to 1.41) 
* Odds ratios (95% Confidence Intervals) were estimated using participants with one-time use of injections as the reference 
group. 
a Adjusted for age at the index visit, sex, K-L grade, comorbidity status, and SF-12 physical component scores 
¶ A negative change in WOMAC scores indicated improvement ranging from -4.6 to -1.2 for pain, -1.5 to -0.5 for stiffness, 
and -9.9 to -4.1 for physical function.  The minimal threshold was used for creating the categories (e.g., improved pain was 
defined as < -1.2; worsened pain was defined as > 1.2; and no change was defined as -1.2 to 1.2). 
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CHAPTER III 
EFFECT OF INTRA-ARTICULAR INJECTIONS ON PATIENT-REPORTED 
SYMPTOMS IN PERSONS WITH OSTEOARTHRITIS: ANALYSIS WITH 
MARGINAL STRUCTURAL MODELS 
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Abstract 
Objective: Parameters for use of intra-articular injections lacks consensus across clinical 
guidelines.  This study sought to examine the effectiveness of corticosteroid or 
hyaluronic acid injections in relieving symptoms among persons with knee osteoarthritis 
(OA). 
Methods: Using Osteoarthritis Initiative (OAI) data, we applied a new-user design to 
identify participants who initiated corticosteroid or hyaluronic acid injections during the 
study.  We identified 988 participants with follow-up information for at least one year 
who met our eligibility criteria.  The Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) was used to measure knee symptoms (pain, stiffness, 
function).  We used marginal structural models controlling for time-varying confounders 
to estimate the effects of newly initiated injection use compared to non-users over two 
years of follow-up.   
Results: Among 412 participants initiating injections, 77.2% used corticosteroid 
injections and 22.8% used hyaluronic acid use.  Compared to non-users, on average, 
participants reporting corticosteroid injection initiation experienced a worsening of pain 
(yearly worsening: 1.24 points; 95% confidence interval [95% CI]: 0.82 to 1.66), stiffness 
(yearly worsening: 0.30 points; 95% CI: 0.10 to 0.49), and physical functioning (yearly 
worsening: 2.62 points; 95% CI: 0.94 to 4.29) after adjusting for potential confounders 
with marginal structural models.  The hyaluronic acid injections did not show 
improvements of WOMAC subscales (pain: 0.50; 95% CI: -0.11 to 1.11, stiffness: -0.07; 
95% CI: -0.38 to 0.24, and functioning: 0.49; 95% CI: -1.34 to 2.32).   
 
 
47 
 
Conclusions: The initiation of corticosteroid or hyaluronic injection use did not appear to 
reduce symptoms over the two years of follow-up. 
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Introduction 
The prevalence of osteoarthritis (OA) is increasing and in the U.S. with ~ 27 
million people are afflicted with the disease.1 Knee OA is 1 of the 5 leading causes of 
disability among non-institutionalized adults in the U.S.11 OA currently has no cure. The 
goals of OA treatment are to improve pain relief, mobility, quality of life, and delay 
disease progression.12,24,25 Treatments include non-pharmacologic or pharmacologic 
modalities. If non-pharmacologic intervention such as exercise or weight management, 
and/or the use of orally administered medications such as acetaminophen are ineffective, 
intra-articular injections of corticosteroids or hyaluronic acid may offer symptom relief 
for patients with knee OA.12–14 
Despite a large number of studies, the safety and efficacy of intra-articular 
injections remains inconclusive leading to a lack of consensus across clinical 
guidelines.12,24,25 Evidence about the extent to which long-term use of intra-articular 
injections improves patient outcomes is lacking. Recent systematic reviews and meta-
analyses suggest that the effect of US-approved viscosupplement injections can last 
through 26 weeks but there is no similar evidence for corticosteroid injections for persons 
with knee OA.17,26,27 Among patients with milder disease, receiving intra-articular sodium 
hyaluronate appears to slow joint space narrowing compared to placebo.28 For 
corticosteroid injections, there is no difference between treatment and placebo groups in 
joint space changes over two years of follow-up.29 Studies documenting the longitudinal 
impact of patient-reported outcomes on knee OA symptoms are scarce. 
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Despite the lack of evidence and conflicting practice recommendations from 
guidelines, the use of injections is increasing among Medicare beneficiaries newly 
diagnosed with knee OA.54 The cost of long-term injection could be substantial (i.e., 
$1700 to $3700 for viscosupplementation treatments).53 Given the widespread use of 
injections and the rising costs of these treatments,53,85,86 understanding the long-term 
effectiveness of intra-articular injections among persons with knee OA is warranted. 
The aim of this present study was to estimate the effect of intra-articular 
injections use on changes in patient reported symptoms. This study builds on previous 
research in several areas. First, we used data from the Osteoarthritis Initiative (OAI), a 
multi-center study that enrolled participants with radiographically confirmed knee OA 
and conducted annual assessments with validated patient-reported outcomes and 
measures of disease progression. Second, compared to clinical trials,26,27 this longitudinal 
and non-experimental study enabled us to examine injection use over a longer period of 
time and to evaluate treatment benefits in a real-world setting. Last, advanced statistical 
techniques were used that allow us to quantify the effect of injections use over time in a 
more heterogeneous population compared to clinical trials. 
 
Methods 
Data source 
 We used publicly available data from the OAI (http://oai.epi-ucsf.org/). The OAI 
was a longitudinal and prospective cohort study enrolling 4,796 adults aged 45 to 79 
years at baseline using four study sites (i.e., Baltimore, MD; Columbus, 
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OH; Pittsburgh, PA; and Pawtucket, RI). The aims of the OAI study were to examine the 
development and progression of knee OA among adults with symptomatic OA in at least 
1 knee or at least 1 established risk factor. Participants had annual follow-up assessments 
for up to 9 years. Detailed information about the OAI protocol has been described 
elsewhere.31  
 
Study sample and design 
 Figure 3.1 shows the inclusion/exclusion criteria for our study sample. Only 
participants with radiographically confirmed knee OA in at least 1 knee at baseline 
(Kellgren - Lawrence grade ≥ 2) were included (n=2,550). To improve validity of the 
study, we restricted our analysis to “new users” of knee injections.83 As such, participants 
who had reported injection use at baseline were not eligible (n=97). In addition, 
participants indicating no injection use but having missing values for more than half of 
the follow-up visits over the 9 years were also excluded (n=303). From the remaining 
group, we identified participants with and without initiation of injection use during the 
follow-up period. Among initiators, we excluded those reporting use of both injection 
types (concurrent hyaluronic acid and corticosteroid injection users, n=52), those 
reporting the first initiation at year 9 because we had no follow-up data after the 
injections (n=47), and those who reported injection in the affected knee after total knee 
replacement (n=3).  To mimic the study design from clinical trials,29,32 participants whose 
age < 45 years and did not have symptomatic knee OA at baseline were considered 
ineligible for injection use and thus further excluded for non-users. The final analytic 
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sample included 412 participants initiating injection use and 576 non-users. Among those 
initiating injection use with available follow-up information for at least one year, 94 
initiated hyaluronic acid injections and 318 initiated corticosteroid injections. 
 
Use of index knee 
We used an index knee for the analysis based on: 1) radiographic evidence of OA 
and 2) the presence of symptoms (e.g., pain) in the same knee. If only one knee had 
radiographically confirmed OA at baseline, then that knee was used as index knee. If 
participants had radiographically confirmed OA for both knees, then the knee with higher 
pain scores at baseline measured by Western Ontario and McMaster Universities Arthritis 
Index (WOMAC) pain subscale was used as the index knee. If pain scores for both knees 
were equal, then index knee was the one with worse K-L grade. 
 
Assessment of injection use 
 In OAI, injection use was assessed separately for both knees. Participants were 
first asked “During the past 6 months, have you had any injections in either of your knees 
for treatment of arthritis?” For those answering “yes”, two separate questions were posed 
regarding hyaluronic acid or corticosteroid injections use. For hyaluronic acid injections, 
participants were asked: “During the past 6 months, have you had an injection of 
hyaluronic acid (Synvisc or Hyalgan) in either of your knees for treatment of your 
arthritis?” These injections are given as a series of 3 to 5 weekly injections. To assess 
corticosteroid injection use, participants were asked: “During the past 6 months, have you 
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had an injection of steroids (cortisone, corticosteroids) in either of your knees for 
treatment of your arthritis?” For participants whose index knees were censored during the 
follow-up (e.g., due to death, switching injection, and/or having total knee replacement), 
we used available information from the other knee to recapture the sample (16 out of 
412). 
 
Assessment of OA symptoms 
 Knee symptoms were evaluated annually using the WOMAC scales (Likert 
version 3.1) including three subscales: pain (5 items), stiffness (2 items), and physical 
function (17 items).57 Each item of the subscale ranged from 0 to 4 (0=none and 
4=extreme). Responses to items in each subscale were summed to produce the individual 
summary score ranging from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical 
function. Higher WOMAC scores indicate worse symptoms/function. The primary 
outcome was change in each subscale between baseline visit (one year before the 
injection), index visit, and one year after the index visit. 
 
Covariates 
We considered covariates in two groups: time-invariant and time-dependent. 
Sociodemographic factors including sex, race/ethnicity, and income were considered as 
time-fixed covariates measured only at the time of enrollment. Age of participants at time 
of injection treatment initiation was also considered as a time-fixed covariate. Income 
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(from all sources) was measured using self-reported personal family income for the year 
before the enrollment. 
Covariates that were collected annually included clinical characteristics of OA, 
indices of general health status, body mass index (BMI), and use of medications and 
biologically related supplements. These were treated as time-varying covariates. The OAI 
collected comprehensive measurements of OA related clinical characteristics including 
K-L grade, multi-joint symptoms, history of knee injury or surgery, and knee alignment.31 
In the OAI, K-L grade was measured from enrollment to year 4 for every participant. 
Thereafter, K-L grade was measured on a subset of the participants. Among participants 
initiating injections after year 5, we carried the last observation forward for the measures 
of K-L grade from year 487 if no information was available. Multi-joint symptoms were 
present if participants had frequent pain, aching, or stiffness in at least 2 joints other than 
the knee.88 Knee malalignment including varus or valgus deformity was measured and 
recorded using a goniometer. History of knee injuries was present if a prior injury limited 
the participant’s ability to walk for at least 2 days indicating on any previous visit. A 
history of having knee surgery was present if participants indicated that they had 
arthroscopy, ligament repair or meniscectomy on any previous visit. 
The 12-item Short-Form (SF-12) health survey was used to assess general health 
status.66 Physical and mental component summary scores were calculated and range from 
0 to 100. Higher scores indicate better health status. The Centers for Epidemiologic 
Studies Depression Scale (CES-D) was used to evaluate depressive symptoms. Elevated 
depressive symptoms were considered present if participants had a CES-D score >16.68  
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A validated self-administered questionnaire modeled after the Charlson index69 was used 
to develop a comorbidity score which sums weights assigned to comorbid conditions 
(range: 0 to 32, higher scores indicating greater severity in comorbid conditions). The 
comorbidity score was categorized into 0, 1, and ≥2.69 BMI was calculated from 
measured height and weight [weight (kg)/height (m)2] and categorized as less than 25, 
normal weight; 25 to less than 30, overweight; and 30 and over, obese.89 
We considered use of pharmacological treatments such as analgesics and 
biologically related supplements as potential confounders. At each visit, analgesic use 
including acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 
selective inhibitors, opioids, and doxycycline was assessed for the previous 30 days. 
Biologically based supplements including glucosamine, chondroitin sulfate, 
Methylsulfonylmethane and S-adenosylmethionine were also assessed for the previous 30 
days. Both over-the-counter and prescription medications captured in the Medications 
Inventory File or reported by patients in the medication history survey were used to 
define use. 
 
Statistical analysis 
 To understand the potential selection bias that may arise due to “lost to follow-
up”, we first compared the characteristics of sociodemographic and clinical factors and 
concurrent pharmacological treatment use at baseline (one year before initiation), index 
year, and one year after initiation. We also examined the distribution of the outcome 
variables and ruled out departures from normality. We then developed a series of models 
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to derive crude estimates, an estimate adjusted for baseline covariates, and adjusted for 
time-varying confounders using generalized estimating equations (GEEs) for continuous 
outcomes adjusted for within-participant correlation with an unstructured correlation 
matrix.90   
Given the OAI data structure, we considered that previously measured study 
outcomes and time-varying confounders may be simultaneously confounders and 
intermediate variables (Figure 3.2). As a result, the estimated overall treatment effects 
would likely be biased using standard regression models.41 To account for time-varying 
confounders that may lie on the causal pathway from previous treatments to the study 
outcomes, we used marginal structural models to estimate the overall treatment effects of 
injection use through inverse probability of treatment weights.30,33   
The weights were calculated in three steps. First, we estimated time-varying 
stabilized inverse probability treatment weights separately for hyaluronic acid injection 
and corticosteroid injection use using non-users as the comparator at the index and 
follow-up visit. While the numerator was estimated using the conditional probability of 
observed injection use given the baseline characteristics, the denominator was the 
predicted probability of observed injection use at the index and follow-up visit 
conditional on baseline covariates and time-varying confounders (e.g., WOMAC subscale 
scores measured at the prior visit and the same visit as use of injections). To construct 
appropriate weights, we also explored the sensitivity of weights to different model 
specifications at the index visit (Supplementary Table 3.1).40 For three different 
outcomes, we adjusted for the previously measured WOMAC subscales as a potential 
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confounder. Second, since participants were censored due to death, switching injection, 
and/or having total knee replacement during the follow-up, we estimated and 
incorporated the inverse probability of censoring weight to account for the potential 
selection bias due to differential censoring by injections use.30,33 Sociodemographic and 
clinical factors among participants who were censored by censoring mechanisms were 
also examined (Supplementary Table 3.2). Censoring weights were calculated using 
similar approach as treatment weights, except that past treatment use was also added into 
models to estimate the probability of having observed censoring status. Lastly, final 
weights were then calculated as the products of treatment (including index and follow-up 
visits) and censoring weights. In addition to checking the distributions of the final 
weights, we also plotted the log odds of injection use conditional on the covariates to 
examine if there was an adequate degree of variation given observed values against the 
predicted injection use (Supplementary Figure 3.1).91 To minimize the impact of potential 
violations of the positivity assumption, we also truncated the weights at the first and 99th 
percentile.40 
With the final estimated weights, we used weighted linear models adjusted for 
baseline covariates to estimate effects of injection use on changes in symptoms and 
disease progression with 95% confidence intervals (95% CIs). Under the assumptions of 
no unmeasured confounding with correct specifications of treatment and outcome 
models, the beta coefficients from marginal structural models indicated the effects of 
hyaluronic acid or corticosteroid injection use compared to non-users on yearly changes 
in WOMAC scores. Minimal clinically important changes for improvements were 
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defined using previous validation studies ranging from -4.6 to -1.2 for WOMAC pain, -
1.5 to -0.5 for WOMAC stiffness, and -9.9 to -4.1 for WOMAC physical function.61–64 
 
Sensitivity analysis 
 To examine the robustness of findings, we conducted sensitivity analyses to 
account for missing values of covariates. Multiple imputation was performed to handle 
missing data in the context of marginal structural model analyses.92 We applied the Fully 
Conditional Specification method for imputation of missing data using SAS PROC MI 
FCS.93 We first used all available information from the covariates (including the outcome 
variable) as variables in the imputation model to impute the missing values.94  Twenty 
imputed datasets were created. We then incorporated the imputed values to rebuild the 
inverse probability treatment weights and fit the outcome models for each imputed 
dataset. Finally, we combined estimates and generated valid inferences using SAS PROC 
MIANALYZE to compare results. 
 
Results 
Sociodemographic and clinical characteristics of study participants 
 Table 3.1 shows sociodemographic and clinical characteristics of study 
participants at baseline (one year before the injection initiation), index year, and one year 
after the injection initiation among those remaining uncensored during follow-up. This 
provides insight into potential bias due to differential censoring mechanisms over time. 
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 Overall, the majority of study participants were women, non-Hispanic white, 
college graduate or above, and had a household income >$50,000. Among participants 
initiating injection use, most of them had K-L ≥ 3. Both CO injection initiators and non-
users had similar distributions of sociodemographic and clinical characteristics at 
baseline. Men and those with higher household income (e.g., > $50,000) comprised the 
majority of HA injection initiators relative to non-users. Among HA injection initiators, 
33.7% of had K-L grade 4, while 17.4% of non-users had K-L grade 4. During follow-up, 
the proportion of those censored at one year after initiation was 29.8% for HA injection 
initiators relative to the other groups (e.g., CO: 19.9%; non-users: 3.0%). Among those 
who remained uncensored, the distribution of characteristics was similar over time 
compared to the distribution at baseline. 
 
Concurrent pharmacological treatment use 
 NSAIDs were the most commonly reported concurrent-use pharmacological 
treatments among the study groups at baseline (Table 3.2). The majority of injection 
initiators reported analgesic use. Similar to sociodemographic and clinical characteristics, 
both CO injection initiators and non-users had similar distributions of concurrent 
pharmacological treatments use at baseline. Among HA injection initiators, 48.9% 
reported concurrent use of supplements such as glucosamine whereas CO injection 
initiators and non-users reported 30.8% and 27.1%, respectively. During follow-up, the 
distribution of concurrent pharmacological treatment use remained similar over time 
between CO injection initiators and non-users group. However, among HA injection 
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initiators, the use of glucosamine or chondroitin sulfate decreased from baseline to one-
year after initiation (e.g., glucosamine: 48.9% to 36.4%; chondroitin sulfate: 44.7% to 
30.3%). 
 
Effects of injections use on knee OA 
 Table 3.3 shows average effects of initiating corticosteroid or hyaluronic acid 
injection use compared to non-users on patient-reported outcomes. After adjusting for 
potential confounders with marginal structural models, the use of corticosteroid injections 
did not improve WOMAC subscales compared with non-users. On average, the yearly 
changes were 1.24 (95% CI: 0.82 to 1.66) for WOMAC pain, 0.30 (95% CI: 0.10 to 0.49) 
for WOMAC stiffness, and 2.62 (95% CI: 0.94 to 4.29) for WOMAC physical function. 
While results from sensitivity analyses were qualitatively similar to our main findings, 
the effect of estimates for WOMAC pain did not meet a priori definitions of minimal 
clinically important differences. 
 While the use of hyaluronic acid injections did not show improvements of 
WOMAC subscales compared with non-users, the magnitude of effects were relatively 
smaller compared to corticosteroid injections use. On average, the yearly changes were 
0.50 (95% CI: -0.11 to 1.11) for WOMAC pain, -0.07 (95% CI: -0.38 to 0.24) for 
WOMAC stiffness, and 0.49 (95% CI: -1.34 to 2.32) for WOMAC physical function.  
The findings from sensitivity analyses remained similar. 
 
Discussion 
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 Using data from the OAI, a longitudinal, multi-center, and prospective cohort 
study, we identified 412 participants with radiographically confirmed knee OA initiated 
injection use. Among those, 77.2% initiated corticosteroid injections and 22.8% initiated 
hyaluronic acid injection use. In the 2 years of follow-up, we did not observe reduced 
symptoms associated with the initiation of corticosteroid or hyaluronic injections 
compared with non-users after carefully controlling for potential time-varying and time-
independent confounders with marginal structural models.   
  Among participants initiating corticosteroid injection use compared to non-users, 
our study findings are consistent with a newly updated review.26 It suggests that the use 
of intra-articular corticosteroids does not support benefits of improved symptoms in the 
long-term after stratifying results by length of follow-up. However, the study duration 
included in the review ranged from two weeks to one year and mixed single injection and 
multiple injection use. To our knowledge, there are only 2 published trials that are 
comparable to our study design that assessed the effect of continuous intra-articular 
corticosteroid use over two years.29,95 Our results are consistent with both studies and 
demonstrate that the use of corticosteroid injections over two years do not appear to 
reduce symptoms.29,95 Despite the fact that, more studies with adequate power and proper 
design may still be needed, our findings do contribute to the growing body of evidence 
produced using non-experimental study design with advanced analytical techniques. 
 With respect to changes in symptoms, our results did not appear to support the use 
of hyaluronic acid injections. Although our findings are not consistent with evidence 
from reviews and meta-analysis,27,96 there are some issues that may hamper the 
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comparison. First, the follow-up periods in trials included in the reviews are mostly short-
term with only one treatment cycle. As such, the beneficial effects of long-term use 
remain unclear. Studies with longer follow-up periods using multiple treatment cycles 
may be needed. In addition, the potential efficacy of hyaluronic injections to patients with 
more severe disease remains unknown since some trials excluded patients with severe 
knee OA. In our study, we observed a substantial percentage of participants initiating 
these injections had K-L 4.   
 Currently, the evidence from systematic reviews and meta-analysis is not 
conclusive about the effects of hyaluronic acid injections use.27,96–98 One of the 
explanations is the potential for publication bias since some reviews selected small and/or 
poor quality trials with positive results.97,98 In addition, evidence from clinical trials is 
also mostly generated from small studies within a shorter period.99 When using only 
results from larger trials with better quality, later updated reviews suggested that the use 
of hyaluronic acid injections compared to non-users is associated with small but not 
clinically important improvement in knee symptoms.97,98 Indeed, for changes in 
symptoms, our results are consistent with the study with a larger sample size over one 
year of follow-up.100   
 The efficacy of both corticosteroid and hyaluronic injections for knee OA patients 
remains in question. Nevertheless, the use of both types of injections is increasing.54 
More information about the comparative efficacy of these common treatments is needed 
for patients, clinicians, and decision makers. Regarding the efficacy of corticosteroid and 
hyaluronic injections, most trials only compare with placebo and the differential effect 
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between the two injections is less clear. While a systematic review suggested 
corticosteroid injections were more effective for pain in the first 4 weeks, a recently 
published trial suggested that the use of corticosteroid injection had similar effects on 
symptom relief for the first two weeks relative to hyaluronic acid injection.17,101 We 
recognize that an active-comparator design offers several advantages.102 However, we 
were not able to use this design with the OAI dataset. Because the proportion of 
participants continuing injection use in the subsequent year was small in our study, we 
were not able to construct inverse probability treatment weights needed for active 
comparison.103   
Our study has several strengths. To avoid overestimating the treatment benefits, 
we used a new-user design by studying treatment initiators.83 To minimize confounding 
by indication, we included comparable participants who did not receive injections by 
using detailed information regarding disease severity. To address threats to the validity of 
the study such as time-varying confounders and “lost to follow-up”, we used advanced 
statistical techniques of inverse probability treatment weights with marginal structural 
models.30 We further performed sensitivity analyses using multiple imputation to 
evaluate the robustness of the main results. Under the same study design, analytic 
techniques, and outcome definition, the results from sensitivity analyses showed 
consistent findings.  
 Several limitations are also acknowledged. First, no information was available on 
the formulation of injections as well as dosages used. Currently, there are several 
molecular weights available for hyaluronic acid injections98 and several different 
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corticosteroid formulations. Second, there is a potential for mismatch between the time of 
injection use and outcome assessments. For example, at annual assessment visits when 
participants were asked about injections used, they could be in the middle of treatment 
cycle. Therefore, the treatment effects could be underestimated. Third, residual 
confounding is still a possibility despite the comprehensive assessments of disease 
severity and concurrent treatment use in the OAI. Lastly, in the practice of constructing 
appropriate weights, there could be a model misspecification and/or violation of 
positivity assumption.40 However, we carefully constructed weights using an iterative 
process and graphically examined if there was an adequate degree of variation given 
observed and predicted injection use. We also truncated weights to minimize the potential 
impact of violating the positivity assumption.40 
 In conclusion, in patients with knee OA, initiating treatments with either 
corticosteroid or hyaluronic acid injections was not associated with reduced symptoms 
compared to non-users over two years. Future research targeting comparative 
effectiveness of these commonly used injections may be helpful to understand the 
usefulness of these treatments for patients with knee OA.  
64 
 
Figure 3.1: Flowchart of study participants.  
 
  
OAI participants: n=4,796  
Participants with radiographic knee OA: 
n=2,550 
Participants not using corticosteroid / hyaluronic acid 
injections at baseline: n=2,150 
(1) Initiating injection use (n=514) 
(2) non-users (n=1,636) 
Exclusions:  
(1) 97 had use of corticosteroid / hyaluronic 
acid injections at baseline 
(2) 303 not indicating any injections use but 
having missing values for more than half of 
the follow-up visits 
 
Users with at least one year of follow-up (n=412):  
(1) Hyaluronic acid injections (n=94) 
(2) Corticosteroid injection (n=318) 
 
Non-users eligible for injections use (n=576): 
(1) Age ≥ 45 years 
(2) Had any pain, aching, or stiffness in or around knee(s) 
on most days for at least one month during the past 12 
months 
(3) WOMAC pain subscale score ≥2 
Exclusions: 
(1) 52 concurrent users 
(2) 47 no follow-up information due to the 
first initiation at year 9 
(3) 3 had injections use after total knee 
replacement 
(4) 1,060 non-users ineligible for injection use 
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Figure 3.2: Directed acyclic graph (causal diagram) between the initiation of injection use, study outcomes, censoring, and 
potential time-varying confounders. 
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Table 3.1: Sociodemographic and clinical characteristics among participants with radiographically confirmed knee OA by use 
of injections. 
Characteristics 
Baselinea Index year One year after injection initiation 
CO HA Non-user CO HA Non-user CO HA Non-user 
Total n* 318 94 576 318 94 576 257 66 559 
Proportions 
relative to baseline 
100 100 100 100 100 100 80.1 70.2 97.0 
Injection use (n) 0 0 0 318 94 0 63 15 0 
 Mean and Percentage 
Mean age (years, 
(SD)) 
66.9 
(9.2) 
65.0 
(8.6) 
64.0 
(9.3) 
67.9 
(9.2) 
66.0 
(8.6) 
65.0 
(9.3) 
68.5 
(9.1) 
66.0 
(8.8) 
65.8 
(9.4) 
Women 64.2 44.7 55.6 64.2 44.7 55.6 65.4 43.9 55.5 
Ethnicity/Race          
  Non-Hispanic 
white 
77.4 88.3 67.9 77.4 88.3 67.9 75.5 87.9 67.4 
  Non-Hispanic 
black 
17.9 6.4 30.0 17.9 6.4 30.0 21.0 7.6 30.4 
  Other 4.7 5.3 2.1 4.7 5.3 2.1 3.5 4.6 2.2 
Education          
  High school or 
less 
18.6 12.9 20.9 18.6 12.9 20.9 20.2 10.8 20. 
  Some college 27.1 23.7 26.7 27.1 23.7 26.7 28.8 24.6 27.1 
  College graduate  22.1 20.4 19.2 22.1 20.4 19.2 19.5 18.5 19.8 
  Graduate school  32.2 43.0 33.3 32.2 43.0 33.3 31.5 46.2 32.9 
Income ($)          
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  <25,000 15.5 4.3 17.9 15.5 4.3 17.9 17.1 4.6 18.1 
  25,000 - 50,000 30.9 22.6 27.8 30.9 22.6 27.8 32.7 16.9 27.6 
  >50,000 53.6 73.1 54.3 53.6 73.1 54.3 50.2 78.5 54.3 
K-L grade          
  2 40.1 22.1 52.3 35.7 16.3 50.0 38.9 22.2 50.7 
  3 39.1 44.2 30.3 37.9 45.0 30.8 41.2 46.3 31.2 
  4 20.8 33.7 17.4 26.4 38.8 19.3 19.9 31.5 18.2 
Symptom-related 
multi-joint OA 
55.4 57.5 55.2 55.7 60.6 50.4 56.0 62.1 49.0 
History of knee 
injury 
40.6 57.5 49.3 47.2 58.5 50.2 49.4 57.6 51.2 
History of knee 
surgery 
28.6 48.9 34.6 32.1 54.3 35.8 35.8 50.0 35.2 
Body Mass Index 
(kg/m2) 
         
  <25  12.9 14.9 13.2 12.9 16.0 13.0 12.1 15.2 14.5 
  25 - <30  40.6 31.9 39.7 40.6 30.9 37.7 40.5 31.8 36.3 
  ≥30  46.5 53.2 47.1 46.5 53.2 49.3 47.5 53.0 49.2 
Knee alignment          
  Normal 20.5 18.9 18.4 17.4 15.9 15.9 18.4 11.9 16.0 
  Varus 39.3 40.0 41.9 42.9 44.3 45.9 38.2 44.1 46.5 
  Valgus 40.3 41.1 39.7 39.7 39.8 38.2 43.4 44.1 37.5 
CES-D (>16) 11.0 8.9 11.0 14.3 12.2 13.3 13.2 12.9 12.1 
Charlson 
Comorbidity Index 
         
  0 65.4 70.2 65.7 62.0 71.0 63.4 56.7 78.5 63.0 
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  1 18.2 22.3 19.3 19.9 20.4 19.9 21.7 15.4 19.9 
  ≥2 16.4 7.5 15.1 18.0 8.6 16.7 21.7 6.2 17.1 
 Mean (standard deviation) 
WOMAC Pain 5.0 (3.9) 5.1 (3.9) 4.9 (4.1) 6.2 (4.2) 5.7 (3.6) 4.4 (3.9) 5.6 (4.0) 5.2 (3.7) 4.2 (3.8) 
WOMAC Stiffness 2.7 (1.7) 2.5(1.7) 2.5 (1.8) 2.8 (1.7) 2.8 (1.6) 2.4 (1.8) 2.7 (1.7) 2.5 (1.6) 2.2 (1.8) 
WOMAC Physical 
Function 
16.8 
(13.0) 
16.7 
(11.8) 
15.3 
(13.0) 
19.2 
(13.2) 
17.1 
(11.3) 
14.4 
(12.8) 
17.9 
(13.2) 
16.9 
(11.1) 
14.1 
(12.8) 
KOOS-QoL 54.6 
(19.9) 
52.2 
(18.8) 
56.0 
(21.7) 
48.3 
(20.2) 
49.0 
(20.1) 
57.4 
(22.4) 
50.6 
(20.3) 
50.5 
(19.5) 
58.4 
(22.0) 
SF-12 Physical 
Component Score 
42.8 
(9.6) 
42.7 
(9.2) 
44.8 
(9.7) 
40.8 
(9.4) 
40.8 
(9.9) 
44.4 
(10.1) 
41.1 
(9.5) 
40.6 
(9.3) 
44.4 
(10.0) 
SF-12 Mental 
Component Score 
54.1 
(8.4) 
55.4 
(7.1) 
53.8 
(8.3) 
54.1 
(9.5) 
55.4 
(8.2) 
53.4 
(9.3) 
53.6 
(9.1) 
55.1 
(8.5) 
53.2 
(9.2) 
Joint space width 
(mm) 
4.6 (1.9) 4.2 (2.2) 5.1 (1.6) 4.4 (1.9) 4.0 (2.1) 4.9 (1.7) 4.4 (1.9) 4.3 (2.1) 4.9 (1.6) 
Abbreviations: SD, standard deviation; K-L grade, The Kellgren–Lawrence grade; CES-D, Centers for Epidemiologic Studies 
Depression Scale; WOMAC, The Western Ontario and McMaster Universities Osteoarthritis Index; KOOS-QoL, Knee injury 
and Osteoarthritis Outcome Score Quality of life subscale. 
 
a One year before the index year. 
* Number of participants with missing information:  
At baseline: education (4), income (3), KL grade (114), body mass index (1) knee alignment (99), CES-D (63), Charlson 
Comorbidity Index (5), WOMAC Pain (29), WOMAC Stiffness (27), WOMAC Physical function (3), KOOS-QoL (27), SF-12 
Physical Component Score (70), SF-12 Mental Component Score (70), joint space width (234). 
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At index year: education (4), income (3), KL grade (153), knee alignment (123), CES-D (72), Charlson Comorbidity Index 
(5),WOMAC Pain (25), WOMAC Stiffness (27), WOMAC Physical function (41), KOOS-QoL (27), SF-12 Physical 
Component Score (93), SF-12 Mental Component Score (93), joint space width (300). 
 
One year after injection initiation: education (3), income (2), KL grade (145), knee alignment (120), CES-D (80), Charlson 
Comorbidity Index (6), WOMAC Pain (56), WOMAC Stiffness (56),WOMAC Physical function (71), KOOS-QoL (56), SF-
12 Physical Component Score (93), SF-12 Mental Component Score (93), joint space width (292). 
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Table 3.2: Concomitant use of medications and supplements among persons with radiographically confirmed knee OA by the 
use of injections.  
Baseline Index year One year after injection 
initiation 
CO HA Non-
user 
CO HA Non-
user 
CO HA Non-
user 
 Percentage 
Use of analgesics          
Acetaminophen  23.6 21.3 16.2 22.0 19.2 12.3 21.4 18.2 14.5 
NSAIDsa 35.2 39.4 31.5 37.3 42.6 28.3 38.4 40.9 27.7 
COX-2 inhibitors 10.4 11.7 4.2 7.2 12.8 3.1 7.8 7.6 3.4 
Opioids 9.4 8.5 8.7 12.9 11.7 6.9 14.8 12.1 8.1 
Any use of analgesics 55.0 56.4 44.4 58.5 63.8 39.6 57.6 57.6 38.6 
3+ 4.7 8.5 1.9 3.5 5.3 1.7 5.8 6.1 2.0 
2+ 17.9 14.9 12.7 17.3 17.0 8.0 16.3 13.6 10.9 
Use of supplements          
Glucosamine 30.8 48.9 27.1 34.6 44.7 25.9 26.9 36.4 21.8 
Chondroitin sulfate 27.4 44.7 24.8 30.5 41.5 22.9 24.5 30.3 19.5 
Methylsulfonylmethane 8.2 14.9 6.9 10.1 20.2 8.3 9.0 19.7 9.3 
S-adenosylmethionine 0.3 1.1 0.4 0.9 0 0.5 0.8 0 0.5 
Other current 
prescribed medications 
         
Doxycycline 0 0 0.5 0.3 0 0 0 0 0.2 
Vitamin D 0.3 3.2 0.5 0.6 5.3 2.2 2.8 3.0 2.5 
Medications for 
osteoporosis 
11.0 7.5 8.0 8.8 7.5 7.1 7.4 4.6 6.1 
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Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs. 
 
a Including self-reported over-the-counter use and current prescriptions such as Aspirin, Ibuprofen, and Salicylate. 
 
* Number of participants with missing information:  
At baseline: NSAIDs (29), Doxycycline (27), Vitamin D (27). 
At index year: NSAIDs (31), Doxycycline (26), Vitamin D (31). 
 
One year after injection initiation: NSAIDs (58), Doxycycline (40), Vitamin D (43). 
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Table 3.3: Estimated effects of injection use compared with non-users on symptoms among persons with radiographically 
confirmed knee OA. 
 Use of CO  
(β* coefficient (95% CI)) 
Use of HA  
(β* coefficient (95% CI)) 
WOMAC pain subscale   
Crudea 1.17 (0.80 to 1.54) 0.77 (0.17 to 1.38) 
Baseline covariatesb 3.49 (-2.36 to 9.33) 0.58 (0.07 to 1.09) 
Baseline plus time-varying covariatesc  2.11 (0.70 to 3.53) 0.40 (-0.30 to 1.10) 
Marginal structural modeld 1.24 (0.82 to 1.66) 0.50 (-0.11 to 1.11) 
Sensitivity analysis 0.51 (-0.31 to 1.32) 0.42 (-1.44 to 2.29) 
WOMAC stiffness subscale   
Crudea 0.23 (0.04 to 0.43) 0.28 (-0.03 to 0.59) 
Baseline covariatesb -0.55 (-1.27 to 0.17) -2.10 (-2.35 to -1.85) 
Baseline plus time-varying covariatesc  0.05 (-1.08 to 1.18) 0.17 (-0.17 to 0.51) 
Marginal structural modeld 0.30 (0.10 to 0.49) -0.07 (-0.38 to 0.24) 
Sensitivity analysis 0.14 (-0.21 to 0.50) -0.43 (-1.54 to 0.67) 
WOMAC physical function subscale   
Crudea 2.60 (1.36 to 3.84) 1.21 (-0.70 to 3.12) 
Baseline covariatesb -1.73 (-9.50 to 6.05) 1.16 (-0.50 to 2.83) 
Baseline plus time-varying covariatesc  0.06 (-0.51 to 0.62) -0.37 (-2.45 to 1.71) 
Marginal structural modeld 2.62 (0.94 to 4.29) 0.49 (-1.34 to 2.32) 
Sensitivity analysis 1.05 (-1.23 to 3.33) 3.84 (-3.72 to 11.40) 
Abbreviations: CO, corticosteroid; CI, confidence interval; GEE, generalized estimating equations; HA, hyaluronic acid; 
WOMAC, The Western Ontario and McMaster Universities Arthritis Index. 
* A negative β coefficient indicates improvement for the Western WOMAC subscales and worsening for the joint space width. 
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a Values derived from GEE models used an unstructured correlation matrix. 
b Models were adjusted for baseline characteristics including age, sex, race/ethnicity, education, income, Kellgren-Lawrence 
grade, body mass index, history of knee injury, history of knee surgery, Short Form 12 physical and mental component 
summary scores, WOMAC subscales, and use of analgesics and glucosamine.  
c In addition to baseline covariates, time-varying confounders including Kellgren-Lawrence grade, history of knee injury and 
surgery, WOMAC subscales, and Short Form 12 physical and mental component summary scores measured at the same visit 
as injection use were also adjusted. 
d Inverse probability-weighted analyses with truncated weights were used. 
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Supplementary Table 3.1: Model specifications for the construction of inverse probability weights at the index visit. 
Specification Descriptiona Estimated weights 
Mean SD Median IQR Minimum Maximum 
1 Numerator includes 
linear terms for baseline 
WOMAC subscales, 
SF12 PCS &MCS, and 
KOOS QoL in addition 
to baseline categorical 
variables such as KL 
grade, injury & surgery 
Hx, and BMI 
 
Denominator also 
includes WOMAC 
subscales, KL grade, 
and KOOS QoL at the 
index visit 
1.02 0.64 0.89 0.53 0.15 6.69 
2 Numerator and 
denominator are as in 
specification 1, but 
without KL grade and 
1.03 0.52 0.93 0.48 0.10 4.02 
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KOOS QoL at the index 
visit in denominator 
3 Numerator and 
denominator are as in 
specification 2, plus 
adding WOMAC 
subscale*WOMAC 
subscale at the index 
visit in denominator  
1.00 0.54 0.88 0.46 0.18 3.96 
4 Numerator and 
denominator are as in 
specification 3, but 
replace linear terms for 
time-varying WOMAC 
subscales with 
categories 
0.96 0.24 0.93 0.19 0.50 2.37 
Abbreviations: SD, standard deviation; IQR, interquartile range 
a All models include age, sex, race/ethnicity, education, and household income at enrollment. 
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Supplementary Table 3.2: Sociodemographic and clinical factors among people with 
radiographically confirmed knee OA by censoring mechanisms. 
Characteristics 
Death 
 
(n=3) 
Total knee 
replacement 
(n=52) 
Switching 
 
(n=34) 
Non-
censored 
(n=323) 
 
Mean and Percentage 
HA initiator 33.3 32.7 29.4 20.4 
Mean age (years, (SD)) 65.7 (6.7) 68.8 (8.9) 65.4 (9.9) 66.2 (9.0) 
Women 33.3 48.1 67.7 61.0 
Ethnicity/Race     
  Non-Hispanic White 100.0 90.4 79.4 78.0 
  Non-Hispanic Black 0 3.9 5.9 18.3 
  Other 0 5.8 14.7 3.7 
Education     
  High school or less 0 17.6 8.8 18.3 
  Some college 0 19.6 23.5 28.0 
  College graduate  0 31.4 32.4 19.3 
  Graduate school  100.0 31.4 35.3 34.5 
Income ($)     
  <25,000 0 7.8 5.9 14.6 
  25,000 - 50,000 0 27.5 29.4 29.8 
  >50,000 100.0 64.7 64.7 55.6 
KL grade     
  2 0 4.1 41.9 41.1 
  3 33.3 42.9 25.8 41.4 
  4 66.7 53.1 32.3 17.5 
Symptom-related multi-
joint OA 
33.3 59.6 50.0 56.0 
History of knee injury 33.3 57.7 44.1 42.4 
History of knee surgery 33.3 38.5 32.4 32.5 
Body Mass Index 
(kg/m2) 
    
  <25  0 17.3 17.7 12.4 
  25 - <30  33.3 42.3 44.1 37.5 
  ≥30  66.7 40.4 38.2 50.2 
Knee alignment     
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  Normal 0 17.7 28.1 19.9 
  Varus 66.7 54.9 34.4 37.0 
  Valgus 33.3 27.5 37.5 43.1 
CES-D (>16) 100.0 6.1 6.5 11.7 
Charlson Comorbidity 
Index 
    
  0 33.3 63.5 70.6 66.9 
  1 33.3 19.2 17.7 19.2 
  ≥2 33.3 17.3 11.8 13.9 
 Mean (standard deviation) 
WOMAC Pain 2.0 (3.5) 5.5 (3.1) 5.2 (3.5) 5.0 (4.0) 
WOMAC Stiffness 1.0 (1.7) 2.7 (1.7) 2.8 (1.5) 2.6 (1.7) 
WOMAC Physical 
Function 
7.8(12.6) 19.4 (11.2) 17.4 (11.4) 16.4 (13.0) 
KOOS-QoL 66.7 (20.1) 48.7 (18.5) 52.7 (14.4) 54.9 (20.2) 
SF-12 Physical 
Component Score 
30.6 (12.1) 41.6 (9.0) 40.6 (7.8) 43.3 (9.6) 
SF-12 Mental 
Component Score 
59.9 (4.8) 56.6 (7.0) 56.5 (6.8) 53.8 (8.4) 
Joint space width (mm) 4.5 (2.1) 2.7 (1.9) 4.1 (1.8) 4.8 (1.9) 
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Supplementary Figure 3.1: Graphical representation of evaluation the experimental 
treatment assumption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(A) Corticosteroid injection initiators 
(B) Hyaluronic acid injection initiators 
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CHAPTER IV 
MISSING DATA IN MARGINAL STRUCTURAL MODELS: A PLASMODE 
SIMULATION STUDY COMPARING MULTIPLE IMPUTATION AND 
INVERSE PROBABILITY WEIGHTING 
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Abstract 
Objective: The use of marginal structural models (MSMs) to estimate unbiased causal 
effects in the presence of time-varying confounding has increased in 
pharmacoepidemiologic studies.  Longitudinal studies are prone to missing data, 
however, recommendations for missing data techniques used in MSMs are contradictory. 
We compared the validity and precision of MSM estimates using multiple imputation 
(MI), inverse probability weighting (IPW), and complete case analysis (CC) in the 
presence of missing data on a time-independent, a time-varying , or both confounders. 
Methods: Datasets were generated using the plasmode simulation framework which 
preserved underlying associations without modifying the exposure or other covariates.  
We constructed the cohort sub-study using data from the Osteoarthritis Initiative which 
estimated the marginal causal effect of intra-articular injection use (binary treatment) on 
one-year symptom change (continuous variable).  We simulated scenarios through 
introducing three missing data mechanisms: 1) missing completely at random (MCAR); 
2) missing at random (MAR); and 3) missing not at random (MNAR).  We also varied 
the proportion of missingness (10%, 30%, and 50%) and whether the confounder subject 
to missing data was fixed to the measurement at baseline or time-varying.  Overall, 81 
simulated scenarios were generated.  Performance of methods was compared using 
relative bias, mean squared error (MSE) of the estimates of interest, and empirical power.  
Results: Regardless of scenarios, estimates of relative bias using CC and IPW were 
similar (relative bias: CC, -0.18% to 3.70 %; IPW, -2.33% to 4.64%), with estimates 
exceeding 15% for scenarios with 50% MNAR on either a time-independent or a time-
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varying confounder, or both.  From MI procedures, relative bias estimates ranged from -
1.88% to 4.24%.  For most scenarios, estimates using MI had smaller MSE (range: 0.013 
to 0.024) than IPW (range: 0.027 to 0.22) and CC (range: 0.027 to 0.215).  While the MI 
procedure maintained empirical power across scenarios, the power decreased using CC 
and IPW given increasing proportion of missingess across different types of miss data. 
Conclusions: Compared to CC and IPW, MI produced less biased estimates with better 
precision over a range of type and extent of missingness.  MI may confer an advantage 
over IPW in MSMs applications. 
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Introduction 
Marginal structural models (MSMs) using inverse-probability-of-treatment–
weighted estimation (IPTW) have been proposed to estimate unbiased causal effects 
when time-varying confounding is a concern.30,41,43 Briefly, this technique creates a 
pseudo-population in which bias has been eliminated by simultaneously adjusting for 
time-varying confounding (without blocking indirect effects from former exposures30 and 
avoiding collider-stratification bias104) and selection bias owing to informative 
censoring.41 Methodologic research has provided guidance on appropriate weight 
construction,40 how best to build the outcome models,91,105 and what assumptions are 
needed to identify consistent causal effects.106,107 Little guidance, however, exists 
regarding how to handling missing data in the longitudinal data used by MSMs.  
To our knowledge, there are two studies comparing methods to handle missing 
information of covariates in the setting of MSMs.92,108 Both of these studies limited their 
evaluation to situations with missing data in time-varying confounders. The guidance 
provided from these studies appears to be contradictory. While one study recommends 
that multiple imputation (MI) is superior to inverse probability weighting (IPW) where 
missing data are strongly predicted by the available data,92 the other suggests that IPW 
performs better than MI.108  Whether the differences in the study findings could be due to 
the effect of the confounder on the outcome108 or some artifact of the simulations is 
unknown. Specific guidance regarding which missing data techniques should be used for 
scenarios of associations between confounders and exposure-outcome relationship is still 
unclear. Further, the extent of biases resulting from applying commonly used missing 
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data techniques for time-independent confounding in MSMs settings has yet to be 
explored. 
Given the increase in applying MSMs,109 the objective of this study was to 
compare validity and precision derived from commonly used missing data approaches 
(i.e., MI and IPW) through simulation studies in the presence of either missing time-
independent or time-varying confounders in cohort studies using MSMs. We evaluated 
the performance of these missing data techniques using plasmode simulation which 
generates simulated data with preserved underlying association among observed 
covariates and exposure data from an empirical cohort study.44 
 
Methods 
 The University of Massachusetts Institutional Review Board considered this study 
exempt since we used publicly available data to construct the cohort for simulation. 
 
Empirical data 
 To create simulated datasets using a plasmode simulation framework, we used 
data from a previously published retrospective cohort study using publicly available data 
from Osteoarthritis Initiative (OAI).110  OAI is a multi-center (i.e., Baltimore, MD; 
Columbus, OH; Pittsburgh, PA; and Pawtucket, RI), longitudinal, prospective 
observational study examining not only the development and progression of knee 
osteoarthritis (OA) but also the effectiveness of disease-modifying therapies. The original 
cohort includes 4,796 men and women ages 45-79 enrolled between February 2004 and 
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May 2006 and followed for 9 years (http://oai.epi-ucsf.org/). The OAI collects not only 
clinical assessments such as symptoms and function of the knee, quality of life, physical 
performance, health behaviors, medications, and supplements of all participants but also 
biologic specimens including blood and urine for up to 9 years of follow up. In addition, 
radiographic and magnetic resonance imaging (MRI) studies were collected. Data on 
clinical, joint status, and risk factors for the progression and development of knee OA 
were collected at baseline and the yearly follow-up clinic visits. In the published study, 
the use of intra-articular injection was evaluated using a “new-user design” among 
participants with knee OA.110 This is an ideal setting to have when applying plasmode 
simulation.44 Using the sample derived in the study, we used participants initiating 
corticosteroid injection and non-users to construct the cohort. Only complete cases that 
provided all of the information were used for generating simulated datasets. This resulted 
in a cohort consisting of 646 participants. 
 
Data generation: plasmode simulation 
 We simulated datasets under the framework of plasmode simulation.44 The causal 
diagrams in Figure 4.1 depict the causal relationship among the injection use, outcome, 
covariates, and missing data mechanisms. While L0 indicates a set of all pre-specified 
confounders from baseline, Lt represents time-varying confounders measured at time t. C’ 
indicates a set of potential confounders in addition to the pre-specified confounders that 
are selected in the data generating mechanism. Some arrows are omitted due to the 
simplicity for presentation. Missing data mechanisms including missing completely at 
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random (MCAR), missing at random (MAR), and missing not at random (MNAR) are 
represented by M. 
 The first step to generate data under the plasmode simulation framework was to 
estimate a linear model with the observed study outcome as a function of the exposure 
status, baseline covariates, and a subset of the potential confounders using data from the 
constructed cohort.110 This estimated model was then used as the basis of the outcome-
generating model later in the data generation process. Next, we sampled with replacement 
among those exposed and unexposed participants from the constructed cohort to achieve 
the desired sample size to compare findings with previous studies.92,108 Since the 
information on covariates and exposure data for each participant was preserved without 
modification, associations among these variables remained complete in the sampled 
population. We then used the outcome-generating model described above to generate 
outcome values through replacing a pre-identified treatment effect on the estimated 
coefficient exposure.   
Table 4.1 shows values of parameters for data generation. We used 1.2 as the pre-
identified treatment effect since this value was considered as the threshold for achieving 
minimal clinically important difference on symptoms change (i.e., knee pain in the 
present study) in patients with knee OA.61–64 Values of all other model coefficients 
remained unchanged and were used to generate the value of outcome status for each 
patient in the simulated data. As such, the outcome Y (i.e., one-year change in knee pain) 
was normally distributed with the expected values generated from the outcome-
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generating model dependent on the pre-identified treatment effect for injection use and 
values of covariates: 
Y = β0 + β1(Injectiont) + β2L0 + β3Lt + β4C’ + ε 
This process was then repeated 1000 times to yield 1000 simulated datasets for each 
scenario of the simulation. 
 
Missing data mechanisms and missing information 
 Based on our experience with missing data in the OAI database in previous 
research,110 we selected the severity of knee OA status (Kellgren-Lawrence grade) 
measured at baseline as the time-independent confounder of interest. Knee pain measured 
at the visit of reporting injection use was used as time-varying confounder.110 We sought 
to evaluate a range of missingness that previous studies used, where 10%, 30%, and 50% 
of the data were imposed as missing.92,108 
Separate simulated datasets were generated for each missing data mechanism 
including MCAR, MAR, and MNAR.45,46 Missing data is considered as MCAR when the 
probability of missing does not depend on the values of observed covariates. To impose 
MCAR in the simulated data sets, we randomly selected participants and forced the 
information on either the time-independent or time-varying confounder to missing. The 
proportion of participants randomly selected varied from 10%, 30%, or 50%. If the 
probability of missing depends on values of observed covariates, it is considered as 
MAR.45,46 To achieve this, we assumed the probability of missing on the time-
independent confounder was a joint function of observed covariates (i.e., age, sex, and 
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visits of reporting injection initiation) that were associated with the measure. For the 
time-varying confounder, we assumed the probability of missing was a joint function of 
observed covariates using information from age, sex, household income, and 
race/ethnicity. This process was accomplished using R package “simstudy”.111 We again 
selected participants to achieve the desired proportion of missingness and forced their 
information on the time-independent or time-varying confounder to missing in each 
simulated dataset. 
MNAR, if it is informative, is when the probability of missing depends on values 
of unobserved covariates.45,46 Using the empirical information from the constructed 
cohort, missing data distributions were imposed so that participants with more severe 
knee OA status (for time-independent confounder) and higher knee pain (for time-
varying confounder) were more likely to be missing. Among all participants missing 
information on Kellgren-Lawrence grade, 30% were randomly selected from Kellgren-
Lawrence grade 2, 50% from grade 3, and 20% from grade 4. For participants with knee 
pain greater than 4, 80% of them were set to be missing. 
 
Inverse probability weighting 
 IPW is not a new approach to handling missing data and is particularly 
straightforward to use in MSMs settings.47,48 It shares the similarity of weight building 
process for the inverse probability of observed treatment or censoring weights that are 
performed by MSMs in estimating causal treatment effects.30 IPW proceeds by 
calculating the probability of having complete data for each individual in the study. Using 
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logistic regression models, contributions of each individual are weighted by the inverse 
probability of having complete data conditional on other relevant covariates. 
 In the missing data mechanisms of MCAR and MAR on the time-independent 
confounder, we modeled the weights of missingness proportional to the inverse 
probability of the value being observed using the logistic regression of M conditional on 
all other available information at baseline from L0 (Figure 4.1). For MNAR, the 
missingess introduced was considered related to some unobserved covariates in the data. 
Since this information was not available, we estimated weights through further included 
other available information at baseline from C’ which potentially were considered to be 
correlated with the missing variable. For missing information on the time-varying 
confounder, a similar approach was used except that now the value being missing was at 
time t. Therefore, we generated the weights of missingness proportional to the inverse 
probability of the value being observed at time t using a logistic model conditional on all 
relevant covariates including injection use, time of initiating injection use, and observed 
values from L0, Lt, and/or C’. 
 
Multiple imputation 
 In general, the approach of MI proceeds by generating m complete datasets where 
missing values in the incomplete observed data are imputed. Each of the m datasets is 
then analyzed using the same model and estimation method. The estimates from each of 
the m datasets are then combined to produce a single estimate that incorporates the usual 
sampling variability as well as the variability of the missing data.49 We used the approach 
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that suggested including all available information (including the outcome) in the data to 
predict missing values for the time-independent and time-varying confounders.112 The MI 
procedure was completed using R package “mice”.113 For each simulated dataset, five 
imputed datasets were generated for the missing information on the time-independent and 
time-varying confounders.114 
 
Analytical approaches and evaluation of methods performance 
 Overall, the analytic approach for this study was carried out in four steps. First, 
we created simulated data sets using the plasmode simulation framework. Second, we 
introduced missing data mechanisms and scenarios to the simulated datasets. Third, we 
then applied IPW and MI to take into account the missing data in the analysis in addition 
to complete case analysis (CC). Lastly, weighted generalized estimating equation (GEE) 
linear models were fit using CC, IPW and MI to estimate the average causal effect in 
MSMs over increasingly problematic scenarios of missingness. In all analyses, we used 
stabilized weights to yield estimates with greater precision compared to the unstabilized 
weight.30,40 The stabilized inverse probability treatment weight (IPTW) was: 
 𝑆𝑊𝑖
𝑡(𝑡) = ∏
Pr⁡[𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖𝑡|𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖𝑡𝐶𝑂𝑁=𝑐𝑜𝑛𝑖𝑡]
Pr⁡[𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆𝑖𝑡=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖𝑡|𝐼𝑁𝐽𝐸𝐶𝑇𝐼𝑂𝑁𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ 𝑖(𝑡−1)=𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅𝑖(𝑡−1)𝐶𝑂𝑁=𝑐𝑜𝑛𝑖𝑡]
, 
While the numerator was the conditional probability of receiving observed treatment 
given baseline confounders, the denominator was the conditional probability of receiving 
observed treatment given time-varying confounders in addition to baseline confounders. 
For the application of IPW, the final weights incorporated in the GEE linear models were 
calculated as the product of stabilized treatment weights and censoring (missing) weights 
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which used a similar approach as described above. For the application of MI, no missing 
weights were needed. However, the analysis was conducted for each imputed dataset.  
Since multiply imputed datasets were used, we used mi.meld function in R package 
“Amelia”.115 Results generated from the function reflected the average estimates with 
standard errors that accounted for average uncertainty and disagreement in the estimated 
values across the models.116   
The performance of methods in each scenario was compared using relative bias, 
mean squared error (MSE), and empirical power of the estimates of interest.  Relative 
bias was calculated as (
?̂?−𝛽𝑡𝑟𝑢𝑡ℎ
𝛽𝑡𝑟𝑢𝑡ℎ
) ∗ 100%. MSE was calculated combining bias and true 
variance (bias2 + standard error(?̂?)2), where standard error(?̂?) was calculated as 
√
1
𝐵−1
∑ (𝛽?̂? − ?̅?)2
𝐵
𝑖=1 .  Empirical power was defined as (1 – empirical type II error) given 
that empirical type II error was calculated as 
#(𝑝>0.05)
𝐵
.  While MSE was used to evaluate 
the accuracy of estimates, empirical power displayed the percentage of time that it will 
reject a false null hypothesis. 
 
Results 
 We overall simulated 81 scenarios with parameter values varied on missing 
mechanisms (MCAR, MAR, and MNAR), percentages of missing (10%, 30%, and 50%), 
type of confounders (time-independent, time-varying, either or both), and analytical 
approaches (CC, IPW, and MI).   
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Table 4.2 shows results from missing values in a time-independent confounder. 
Estimates of relative bias using three missing data approach show similar results while 
the range of IPW is slightly larger (range: CC, -0.18% to 1.61%; MI, -1.16% to -1.88%; 
IPW, -2.33% to 2.01%). Regardless of missing data mechanisms, the performance 
measured by MSE using MI is consistent and smaller across scenarios while CC and IPW 
show a trend of increased estimates given the increasing proportion of missingness. 
Similarly, while the performance of empirical power using MI is maintained across 
scenarios, CC and IPW show a trend of decreased power given the increasing proportion 
of missingness. 
Table 4.3 shows results from missing values in a time-varying confounder. 
Similar to the performance of missing on the time-independent confounder, estimates of 
relative bias using three missing data approaches show similar results regardless of 
scenarios (range: CC, -0.04% to 3.70%; MI, -0.41% to -4.16%; IPW, -0.54% to 4.64%). 
For the three approaches, the largest bias happen when there is a 50% of missingess in 
MNAR (CC: 3.70%; MI: 4.16%; IPW: 4.64%). While MI gives a smaller MSE and 
maintains empirical power across all scenarios, CC and IPW both show a trend of 
increased MSE and decreased power given the increasing proportion of missingness. 
Results from missing values in either a time-independent, time-varying, or both 
confounders is displayed in Table 4.4. While MI shows a relatively smaller bias across 
scenarios (range: -0.55% to 4.24%), CC and IPW give larger estimates of relative bias 
(range: CC, -0.69% to 15.37%; IPW -0.50% to 15.74%). Regardless of missing data 
mechanisms, the relative bias increases to over 10% using CC or IPW when missing 
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information on the confounders reaches to 50%, but not with MI. While MI gives a 
consistently smaller MSE and maintains empirical power across all scenarios, CC and 
IPW both show a trend of increased MSE and decreased power given the increasing 
proportion of missingness. Similar to the estimates of relative bias, the worst scenario 
happens when missing information on the confounders reaches 50% regardless of 
imposed missing data mechanisms. 
 
Discussion 
 Using a plasmode simulation framework with imposed missing data on time-
independent and/or time-varying confounders, our simulation study demonstrated the 
performance of commonly used missing data approaches including CC, IPW, and MI in 
the context of MSMs analyses. Compared to CC and IPW, MI consistently produced less 
biased marginal estimates with better precision regardless of missing data mechanisms 
and the extent of missingness. In addition, while empirical power performed by the MI 
procedure was consistent across scenarios, CC and IPW both displayed a trend of 
decreased power given the increasing proportion of missingness. 
 Our findings are aligned with one of the previous studies showing that the MI 
procedure provided less biased marginal estimates and noticeably less variability given 
imposed missing data mechanisms and the extent of missingness.92 In the implementation 
of the MI technique, baseline information of the confounding variables was provided to 
impute the missing values in both simulation settings. In addition, we also included the 
outcome variable in the prediction model for the time-independent and time-varying 
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confounders.112 However, it is not clear if such approaches were used in the other 
study.108 Since the purpose of MI is to model the missing values, our approaches may 
give additional advantages of MI over IPW if the information provided was predictive of 
the missing variables.  
On the other hand, the goal of the IPW technique focuses on predicting missing 
data mechanisms.117 There may well be some situations where IPW outperforms MI. One 
plausible example includes situations lacking strong predictors of the missing values or 
the missingness mechanism is well-understood. In our setting, we used only fully 
observed covariates to model the missingness. Using this approach, it can ensure that all 
the data needed to fit the missingness model and to estimate individuals’ weights are 
observed.118 However, when data are ‘monotone missing’, non-fully observed predictors 
can be included to model the missingness. In the previous study, missed visits was also 
discussed for one of the missing-data scenarios.108 As scenarios resulted in large numbers 
of consecutive missing values due to missed visits (considered as monotone missing), the 
IPW may yield more satisfactory performance relative to MI. Yet, whether this scenario 
explains the differences among these studies remains unclear owing to lack of 
transparency in reporting. A brief summary to compare IPW and MI approach is 
displayed in Supplementary Table 4.1.  
In addition to comparing method performance using bias and precision, our study 
also demonstrated using MI procedure was able to maintain empirical power consistently 
across scenarios whereas the power decreased using CC and IPW given increasing 
proportion of missingess across different types of miss data. Typically, a strength of a 
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MSMs analysis through applying IPTW using observational studies is that it partially 
mimics a sequentially randomized trial design and thus allows estimation of the marginal 
treatment effect.119 However, similar to findings from CC, we noticed that the statistical 
power to detect a pre-identified non-null treatment effect using IPW was decreased 
compared to MI in our simulated scenarios. This is an important issue since statistical 
power supplies both investigators and readers with information to help interpret 
potentially null conclusions using such an analytic approach. Our findings may thus 
provide additional perspectives regarding the choice of analytic methods when dealing 
with missing data under MSMs settings.  
Several limitations must be acknowledged. First, we considered a simplified 
context which only used a single-time interval setting for data-generating scenarios 
related to treatment use and outcome. For situations involving more time intervals, the 
mechanisms regarding continued treatment use become more complicated. Information 
on time-varying confounders affecting treatment use is needed to correctly model the 
complex mechanism of treatment use.120 Second, the model used to generate outcome 
values was based on a set of pre-defined covariates from a cohort sub-study using data 
from OAI. It is possible that outcomes generated from a much larger set of factors (e.g., 
using data from claims datasets) may be different due to the influence of both measured 
and unmeasured covariates.44 Therefore, the performance of methods observed based on 
this cohort sub-study may not extend to other studies simulated from claims data.  Third, 
while missing data can also occur in the exposure of interest,121 our simulation study only 
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introduced missingness on confounders. Whether our findings extend to different types of 
variables, including the outcome and exposure of interest, needs to be explored. 
Despite the limitations, strengths of our study include the use of plasmode 
simulation in which the covariate data and associations among covariates remain 
unchanged with the advantage to manipulate other parameters such as strength of 
confounders and exposure of interest.44 In addition, using the cohort sub-study from OAI 
to construct the cohort for simulating datasets provided measurements not only on 
clinical assessments (e.g., symptoms and joint status) but also risk factors and concurrent 
medication use for the progression of knee OA. Given the pre-identified potential 
confounders and treatment effect,110 data-generating scenarios in our study may perform 
better than approaches using ordinary methods or healthcare claims which may not 
capture important features of this population. While previous studies focused on time-
varying confounders,92,108 our study also assessed the methods performance using 
baseline confounders and mixed scenarios which provided a more comprehensive and 
realistic evaluation under MSMs analyses. 
 In conclusion, with a range of simulated scenarios under MSMs analyses, our 
simulation study demonstrated that MI generally produced less biased estimates with 
better precision over a range of missing data mechanisms and extent of missingness. 
Moreover, the MI procedure maintained empirical power across scenarios, the power 
decreased using CC and IPW given increasing proportion of missingness across different 
types of missing data. Under simple yet realistically constructed scenarios, MI may 
confer an advantage over IPW in MSMs applications.  
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Figure 4.1: Causal diagrams depicting relationship in simulated datasets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LEGEND: Data generation and missing mechanisms for simulation studies.  L0 indicates a set 
of all pre-specified confounders measured at baseline, Lt represents time-varying confounders 
of the Injection-Y outcome association measured at time t.  C’ indicates a set of potential 
confounders in addition to the pre-specified confounders that are selected in the data 
generating mechanism.  M indicates missing mechanisms.  A) This causal diagram shows that 
missingness (M) is present in the baseline confounder L0; B) This causal diagram shows 
missingness (M) in the time-varying confounder Lt;; and C) This causal diagram indicates that 
missingess (M) is present in either or both baseline or time-varying confounders. 
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Table 4.1: Values of parameters for data generation using plasmode simulation 
framework and Osteoarthritis Initiative data. 
Parameter Meaning Value 
N Sample size 500 
B Total simulations 1000 
M Number of imputed data 
sets 
5 
Missing data mechanism 
for a time-independent or 
a time-varying 
confounder (M)* 
  
MCAR Missing complete at random 10%, 30%, 50% 
MAR¶ Missing at random 10%, 30%, 50% 
MNAR§ Missing not at random 10%, 30%, 50% 
Pr(Injectiont = 1) Probability of initiating 
intra-articular corticosteroid 
injection at time t 
Empirical distribution from 
the constructed cohort: 
~33.0% 
β True simulated effect: the 
difference in one year 
change in knee pain (Y) of 
initiating injection use  
1.2 
Y Predicted values of one year 
change in knee pain depend 
on observed values of 
exposure status and 
confounders 
Y = β0 + β1(Injectiont) + 
β2L0 + β3Lt + β4C’ + ε 
Ε Error term ~N(0,1) 
L Confounders including 
predefined important 
baseline confounders (L0), 
time-varying confounders 
(L1), and other pre-specified 
confounders (C’) 
Empirical distribution from 
the constructed cohort 
* We introduced missing data within the context of a data source given the complete 
information from the measured covariates.  The severity of knee OA status (Kellgren-
Lawrence grade) measured at baseline was used as the time-independent confounder.  
Knee pain measured at the visit of reporting injection use was used as time-varying 
confounder. 
¶ The probability of missing data for the time-independent confounder (Kellgren-
Lawrence grade) or time-varying confounder (knee pain) was a joint function of observed 
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covariates (i.e., age, sex, and time of initiating injection use) associated with each 
variable. 
§ For the time-independent confounder (Kellgren-Lawrence grade), we imposed the 
following missing data distributions.  Among all participants missing information on 
Kellgren-Lawrence grade, 30% were randomly selected from Kellgren-Lawrence grade 
2, 50% from grade 3, and 20% from grade 4.  As such, participants with more severe 
knee OA status were more likely to be missing given the original distribution from the 
constructed cohort. 
For the time-varying confounder (knee pain score), among all participants missing 
information on knee pain scores, 80% of them were randomly selected from pain scores 
greater than 4.  
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Table 4.2: Comparison of percent bias, mean square error, and empirical power for methods to handle missing data (CC, MI, 
IPW) under various mechanisms for missing data and extent of missing data: the case of a missing data in a time-independent 
confounder. 
Abbreviations: CC, complete case; IPW, inverse probability weighting; MAR; missing at random; MCAR; missing completely 
at random; MNAR, missing not at random; MI, multiple imputation; MSE, mean squared error. 
  
Missing mechanism 
and % missing data 
Bias (%) MSE Empirical power 
CC MI IPW CC MI IPW CC MI IPW 
MCAR          
10% -1.19 -1.58 -1.01 0.027 0.015 0.027 99.1 99.9 99.3 
30% -1.68 -1.43 -1.74 0.036 0.014 0.042 96.1 99.6 94.4 
50% 1.61 -1.56 2.01 0.053 0.014 0.064 85.4 99.9 83.7 
MAR          
10% -1.45 -1.46 -1.32 0.028 0.015 0.029 98.9 99.8 98.9 
30% -0.18 -1.16 -0.47 0.035 0.015 0.038 96.7 99.8 95.8 
50% -1.21 -1.83 -0.67 0.054 0.015 0.063 82.1 99.5 80.7 
MNAR          
10% -1.54 -1.88 -1.84 0.028 0.014 0.03 98.9 99.9 98.6 
30% -1.92 -1.20 -3.29 0.039 0.014 0.045 94.0 99.9 92.5 
50% 0.74 -1.72 -2.33 0.067 0.015 0.083 79.4 99.7 71.0 
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Table 4.3: Comparison of percent bias, mean square error, and empirical power for methods to handle missing data (CC, MI, 
IPW) under various mechanisms for missing data and extent of missing data: the case of missing data in a time-varying 
confounder. 
Missing mechanism 
and % missing data 
Bias (%) MSE Empirical power 
CC MI IPW CC MI IPW CC MI IPW 
MCAR          
10% -1.13 -1.59 -1.11 0.028 0.014 0.028 99.0 99.8 99.0 
30% -1.51 -1.01 -1.38 0.04 0.014 0.04 95.3 99.9 95.2 
50% 1.93 -0.84 1.98 0.059 0.015 0.061 86.5 99.4 86.0 
MAR          
10% -0.96 -1.82 -0.94 0.027 0.015 0.027 98.8 99.7 98.8 
30% -0.61 -1.02 -0.54 0.039 0.014 0.039 95.2 99.8 94.7 
50% 1.36 -0.91 1.55 0.061 0.015 0.062 84.4 99.9 84.8 
MNAR          
10% -0.94 -1.44 -0.74 0.028 0.015 0.028 98.9 99.6 98.8 
30% -0.04 -0.41 0.50 0.037 0.014 0.064 97.5 99.8 97.2 
50% 3.70 4.16 4.64 0.062 0.021 0.037 91.4 99.7 92.0 
Abbreviations: CC, complete case; IPW, inverse probability weighting; MAR; missing at random; MCAR; missing completely 
at random; MNAR, missing not at random; MI, multiple imputation; MSE, mean squared error. 
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Table 4.4: Comparison of percent bias, mean square error, and empirical power for methods to handle missing data (CC, MI, 
IPW) under various mechanisms for missing data and extent of missing data: the case of missing data in either a time-
independent confounder, time-varying confounder, or both. 
Missing mechanism 
and % missing data 
Bias (%) MSE Empirical power 
CC MI IPW CC MI IPW CC MI IPW 
MCAR          
10% -1.82 -0.94 -1.82 0.029 0.014 0.029 98.4 99.7 98.2 
30% 1.56 -1.12 1.50 0.066 0.013 0.067 83.6 100 82.5 
50% 11.14 0.39 11.36 0.202 0.014 0.21 47.3 100 46.7 
MAR          
10% -1.14 -0.57 -1.01 0.03 0.013 0.03 98.0 99.9 97.9 
30% 2.27 -0.78 2.33 0.062 0.015 0.063 84.8 99.6 84.3 
50% 10.68 -0.81 10.51 0.198 0.014 0.204 47.8 99.7 47.0 
MNAR          
10% -0.69 -0.55 -0.50 0.028 0.014 0.028 98.4 99.9 98.6 
30% 2.36 0.09 2.81 0.064 0.014 0.066 85.1 100 85.5 
50% 15.37 4.24 15.74 0.215 0.024 0.22 59.0 99.8 59.1 
Abbreviations: CC, complete case; IPW, inverse probability weighting; MAR; missing at random; MCAR; missing completely 
at random; MNAR, missing not at random; MI, multiple imputation; MSE, mean squared error. 
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Supplementary Table 4.1: A brief summary comparing approaches of IPW and MI. 
IPW MI 
 Only use information on complete 
cases 
 Assume model for probability of 
complete cases (“missingness 
model”) 
 Require data to be MCAR or MAR 
 Restriction to complete cases can 
lead to bias 
 If data are “monotone missing”, 
non-fully observed predictors can 
be used 
 Use data on all subjects 
 Assume model for joint 
distribution (“imputation model”) 
 More efficient if some incomplete 
cases have some information 
 Generally more efficient 
 Can deal with MAR and MNAR 
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CHAPTER V 
 DISCUSSION AND CONCLUSIONS 
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The overall purpose of this dissertation was to examine the effectiveness of intra-
articular injection use and changes in knee symptoms over time among patients with knee 
OA living in the community. CO and HA injections have different mechanisms of action 
and are the two primary types of intra-articular injections used in OA. Despite a large 
number of clinical trials addressing the safety and efficacy of intra-articular injection use, 
recommendations across clinical guidelines still remain inconclusive. More importantly, 
evidence about the effects of long-term use of these treatment modalities is still scarce. In 
this dissertation, we used advanced analytical methods such as MSMs and plasmode 
simulations to address methodological challenges including time-varying confounders 
and treatment initiation over time. Findings from this dissertation are summarized below. 
In Aim 1, we first evaluated the complexity of treatment use of intra-articular 
injections after treatment initiation among persons with radiographic knee OA over time. 
We hypothesized that the patterns of injection use among persons with knee OA would 
be associated with more severe symptoms and/or changes in symptoms over time 
compared to those who only received one-time injections. This investigation yielded 
several findings. First, we found that a substantial proportion of knee OA patients who 
initiated intra-articular injections either switched their treatment or used it just once 
during the follow-up period, regardless of the initial therapy or actual change in 
symptoms. Second, approximately 1 in 5 participants initiating injections switched 
injection type. Third, while nearly 1 in 4 hyaluronic acid initiators switched to 
corticosteroid injections, we were surprised to find that almost 1 in 5 corticosteroid 
initiators switched over to hyaluronic acid injections. Given that HA is a newer and more 
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costly treatment for persons with more severe OA, the channeling effect into the 
hyaluronic injections was not clear. Last but not least, our findings did support the 
hypothesis that among initial users of CO injections, worse symptoms after the first 
injection were associated with lower odds of continued treatment use, while changes in 
knee symptoms had no such association. 
 With the information regarding pattern of injection use from Aim 1, we were able 
to examine the extent to which intra-articular injections relieve symptoms among persons 
with radiographic knee OA over time in Aim 2. For this we employed MSMs which 
applied weighting methods to adjust for time-varying confounding and censoring over the 
course of treatment. After carefully controlling for potential time-varying and time-
independent confounders, we did not observe reduced symptoms associated with the 
initiation of CO or HA injections compared with non-users in 2 years of follow-up data. 
However, we did find that the power to detect the difference may be insufficient due to 
the missing information on some potentially important confounders. To address this 
issue, we used MI to conduct sensitivity analyses to account for missing values of 
covariates. Results from sensitivity analysis were qualitatively similar to our main 
findings. 
 For Aim 2, we recognized that the methodologic research on how to handle 
missing data in the longitudinal dataset used by MSMs is limited and conflicting. Thus in 
Aim 3, we set out to evaluate the performance of missing data techniques including CC, 
IPW, and MI within MSMs using a plasmode simulation framework. With imposed 
missing data on time-independent and/or time-varying confounders, we demonstrated MI 
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consistently produced less biased marginal estimates with better precision regardless of 
missing data mechanism and regardless of the extent of missingness compared to CC and 
IPW. In addition, while the MI procedure demonstrated a consistent performance 
measured by empirical power across scenarios, CC and IPW both displayed a trend of 
decreased power given the increasing proportion of missingness. 
 
Limitations and strengths 
While there are several important questions addressed in this dissertation, there 
are several limitations. First, there may be misclassification in reporting injection use. In 
OAI, treatment use was assessed annually. Given the questionnaires used (i.e., 6 months 
window before the annual visit to assess treatment use), we may miss the identification of 
new-users or continued users during the intervals of assessments. For instance, when 
participants were asked about their injection use, the time for their annual assessment 
may be out of the window to report their injection use. On the other hand, given that the 
knee injection is an invasive procedure and patients may be more likely to remember and 
report the use of injections, some participants may still report having injection use even 
when the time of receiving injection was out of assessment window. With these possible 
scenarios, it could be the non-differential misclassification given that these groups may 
have the same probability of being misclassified across all study subjects. If this 
misclassification was non-differential, the treatment effects could be toward the null.122 
Another potential for misclassification could be those “not continued” users may include 
patients who went on to total knee replacement (TKR). However, among those who did 
 
 
107 
 
not continue injection use, only a small portion of participants in this group had TKR 
after the initiation of injection use. After excluding those participants, results were 
comparable to the main findings.  
Second, confounding by indication may arise when individuals have an 
"indication" for use of the drug even if the study population consists of subjects with the 
same disease (e. g., patients with OA).  However, confounding by indication is not 
conceptually different from confounding by other factors, and the approaches to control 
for confounding by indication are the same such as matching, stratification, restriction, 
and multivariate adjustment.123 Through applying IPTW, MSMs allowed us to account 
for changing values of the confounders over time and thus minimize the effect of 
confounding by indication. Moreover, in Aim 2, we further restricted participants who 
had symptomatic knee OA at baseline for non-users to minimize the potential impact of 
this issue.  
Despite that we were able to adjust the indices to deal with the potential 
confounding by indication given the comprehensive measurement and information on the 
disease severity that might affect patients in seeking treatment in OAI,123 we could not 
rule out the possibility that our findings may still be biased by unmeasured confounding 
(e.g., the patients’ preference of  physicians or specialists). In addition, the IPTW 
approach may be biased by a few observations with very high weights in the process of 
constructing appropriate weights. Violations of the positivity assumption are also 
possible due to model misspecification.40 To address these concerns, we carefully 
constructed weights using an iterative process and graphically examined whether there 
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was an adequate degree of variation given observed and predicted injection use. We also 
truncated weights to minimize the potential impact of violating the positivity 
assumption.40,124 In addition, residual confounding is still a possibility despite the 
comprehensive assessments of disease severity and concurrent treatment use in the OAI. 
Nevertheless, several contrasting models were used for illustration including results from 
sensitivity analyses that allowed readers to evaluate the observed associations within the 
context of any limitations of the data.  
Third, despite an initial large sample size, the proportion of participants 
continuing injection use in the subsequent year was small and thus we were not able to 
use an active-comparator design with this dataset. Furthermore, no information was 
available on the formulation of injections and dosages used, so all injections were 
analyzed together regardless of drug. Lastly, we used a single-time interval as the 
simplified setting for data generation and the time-varying confounder used in the study 
was not affected by treatment history. Further information on time-varying confounders 
affecting treatment use is needed to correctly model the complex mechanism of treatment 
use.120 
Despite these limitations, this dissertation has several strengths. Use of advanced 
analytic techniques adds to the body of literature in OA research on intra-articular 
injection use. Our studies were conducted within the OAI, a large, prospective cohort that 
collected a wealth of data on a large number of people with radiographically confirmed 
knee OA. With the data derived from yearly visits within the OAI, we were able to 
identify patients newly initiating injection use. To our knowledge, Aim 1 is the first study 
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examining patterns of intra-articular injections use for patients with knee OA. In addition, 
we applied several advanced analytic methods such as MSMs to estimate the effect of 
time-varying exposures and time-dependent confounders that are affected by prior 
treatment use. The use of MSMs allowed us to obtain less-biased effect estimates than we 
would have observed using a traditional approach. Lastly, compared to ordinary 
simulation methods, using the plasmode simulation framework provided the advantage of 
specifying values of parameters such as strength of confounders and exposure of interest 
given that covariate data and associations among covariates remain intact. While previous 
studies focused on time-varying confounders,92,108 our study also assessed the 
performance of missing data techniques with imposed baseline confounders and mixed 
scenarios which provided a more comprehensive and realistic evaluation under MSMs 
analyses. 
 
Implications and future research 
Given the summary findings from the three specific aims of this dissertation, we 
suggest several clinical and research implications for future work in this area. 
 
Clinical implications 
Findings from this work have yielded several important clinical implications that 
could affect providers’ or patients’ clinical management of knee OA.  First, a consistent 
recommendation is needed for commonly used clinical guidelines. In this work, we 
observed that a substantial proportion of knee OA patients initiating intra-articular 
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injection use switched their treatment or simply used it for one time, regardless of the 
initial therapy or actual symptoms change. Rather than the actual effectiveness of 
treatment, this phenomenon may be due to conflicting recommendations in the 
guidelines. Indeed, it has been suggested that the clinical guidelines for the treatment of 
patients with knee OA should employ a standard “appropriate methodology” to avoid 
confusion among physicians.125 Second, similar to other pain treatments such as 
NSAIDs,12,24,25 a “step-up” approach for intra-articular injections for patients with knee 
OA may be needed. Typically, clinicians may be channeling persons with more severe 
disease into the newest and more costly treatments (e.g., HA injection in this work). 
However, we observed that approximately 1 in 4 participants initiating HA injections 
switched to CO injections and that channeling into the hyaluronic injections was not 
apparent. These findings may suggest a potential lack of increased efficacy. Last but not 
least, given concern about cost-effectiveness, we suggest that patients be informed about 
the long-term efficacy of these commonly used modalities to set accurate expectations 
before deciding on the treatment.  
Patients with more severe disease may receive HA injections as a matter of 
convenience since HA injections may offer longer term benefits compared to CO.25 
However, our work suggests that initiating either CO or HA injection use was not 
associated with reduced symptoms when compared to non-users over two years. Despite 
current literature showing that injections are generally safe and have positive effects for 
patients’ satisfaction,126–128 it is still not clear what proportion of observed measurements 
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are actually from the real disease modifying effect of these treatments or simply a result 
of a placebo effect. 
 
Research implications 
While randomized clinical trials (RCTs) are considered the “gold standard” in 
medical research, using observational data has several advantages. It allows investigators 
to assess effectiveness and safety with the availability of a longer follow-up period.129 
Using a larger sample size with the inclusion of a wide range of patients living in the 
community, researchers can also examine differences in non-primary outcomes and 
improve generalizability of study findings.130 However, unlike RCTs that use 
randomization to make treatment groups balanced, observational studies are limited due 
to non-random comparison groups with confounding factors. Furthermore, using a 
traditional approach to control for confounding including time-varying confounders may 
result in biased estimates of treatment use in longitudinal observational studies.30,41,43  
In this dissertation, we used MSMs with IPTW to estimate the unbiased causal 
effect when time-varying confounding is a concern.30,41,43  Despite the advantages of 
MSMs, we identified several key methodologic areas that may inform future research 
efforts. First, given the cost associated with treatment modalities and inconclusive 
evidence from the literature regarding injection use, future studies may consider use of 
active-comparator design, especially for the head-to-head comparison, when conducting a 
comparative-effectiveness research. While our work had to employ non-users as the 
comparison group to examine the long-term effectiveness of injection use, we recognize 
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that an active-comparator design may build on this work in several areas.102,103 Further, 
considering the use of multiple treatment cycles is also important when studying long-
term effectiveness in the context of injection use. When using evidence from systematic 
reviews, we noticed that follow-up periods in those trials are mostly short-term with only 
one treatment cycle. Therefore, the beneficial effects of long-term use, especially for 
continuous users, remain unclear. In our study, despite evaluation of multiple treatment 
use (i.e., two time intervals), there was a potential for mismatch between the time of 
injection use and outcome assessments. For example, at annual assessment visits when 
participants were asked about injections used, they could be in the middle of a treatment 
cycle. Therefore, the treatment effects could be underestimated. Moreover, it is also vital 
to take into account the information regarding the formulation of injections as well as 
dosages used given that there are several molecular weights available for hyaluronic acid 
injections98 and several different corticosteroid formulations. These factors may affect 
how we define the operational definition for the exposure of interest as well as the 
outcomes observed.131 Finally, given that OA is a heterogeneous disease, it is important 
to identify the subgroups that may potentially benefit most from treatment in future 
clinical research.132,133 This is especially important because sometimes it could be the 
failure to identify and examine subgroups that results in finding no long-term effects on 
structural modification in the knee and/or symptom relief. Therefore, future work may 
require a methodologically robust method to test for a treatment effect in subgroups in 
order to inform novel therapeutic opportunities and clinical applications. 
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Conclusions 
 Taken together, the studies in this dissertation add to the body of literature by 
examining patterns and effects of intra-articular injection use among person with knee 
OA living in the community. The findings from this dissertation suggested that the 
proportion of switching between injection drugs and the proportion of one-time users was 
substantial after treatment initiation. In addition, initiating injection use was not 
associated with reduced symptoms over time. With respect to issues of missing data, 
using MI may confer an advantage over IPW in MSMs applications. The results from this 
work highlight the importance of conducting comparative effectiveness research with 
non-experimental data to study these commonly used injections and may shed light on 
strategic non-surgical treatment solutions by informing patients and clinical prescribers 
who treat persons with knee OA. Future studies should include information on the 
formulation of injections and dosages used and identify subgroups that may benefit most 
from the treatment use. 
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